Treatment needs in first-episode schizophrenia : some additional perspectives by Landolt, Karin
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Treatment needs in first-episode schizophrenia : some additional perspectives
Landolt, Karin
Abstract: The three studies summarised in this cumulative dissertation deal with first- episode schizophre-
nia. The first episode is an especially sensitive moment shaping the course of the illness. Therefore,
research on this phase is important. Treatment during the first episode should target the psychotic
symptoms efficiently, but should also be as less invasive as possible. As antipsychotic medication mostly
fulfils the first criterion, but less often the second criterion, it is legitimate to focus on treatments that
provide relief from symptoms and eventually alternatives to continuous medication. This dissertation
focuses on treatment needs (Studies 1 and 2), which encompass a broader spectrum of topics apart from
medication, and deals with patients who stopped any antipsychotic medication (Study 3). All three stud-
ies were conducted using data from the EUFEST-Trial, a randomised controlled trial comparing first-
versus second-generation antipsychotics in the treatment of first-episode schizophrenia. The trial encom-
passed in total 498 participants recruited in 13 mental health centres from different European countries
and Israel. After a baseline interview, as many participants as possible were followed-up for 12 months.
The longitudinal structure of the data allowed for using Latent Class Growth Analysis (LCGA), which
identifies groups of persons with different courses on one outcome measure. Additionally, cox- regression
and structural equation modelling were implemented. Many different findings emerged from the three
studies. Among other things one study showed that especially unmet social needs persisted over the 12
months, and were often in danger of not being addressed adequately. Especially unmet needs that disap-
peared – instead of being met – were associated with a higher quality of life at follow-up. Moreover, there
were hints that the decision whether to continue with antipsychotic medication or not was not guided
by clear rules, but rather by attitudes, local use, and “rules of thumb”. All those findings might help to
improve treatment of first-episode schizophrenia, and provide ideas for further research. The dissertation
closes with a critical discussion of the concept of treatment needs, the value of secondary analyses, and
the generalisability of the results. Die vorliegende kumulative Dissertation fasst drei Studien zur ersten
Episode der Schizophrenie zusammen. In der ersten manifesten schizophrenen Episode kann der Ver-
lauf der Erkrankung positiv oder negativ beeinflusst werden, was Forschung über diese Phase besonders
wichtig macht. Die professionelle Behandlung sollte in der ersten Episode sowohl auf die Reduktion der
psychotischen Symptome abzielen, als auch so wenig invasiv wie möglich gestaltet sein. Antipsychotis-
che Medikation wirkt wohl antisymptomatisch, erfüllt aber das zweite Kriterium der Nicht-Invasivität
weniger deutlich. Deshalb ist es legitim, nach Behandlungsmodalitäten zu suchen welche Entlastung von
Symptomen und gleichzeitig möglicherweise Alternativen zur kontinuierlichen antipsychotischen Medika-
tion bieten. Diese Dissertation diskutiert Behandlungsbedürfnisse der Patienten, und somit ein breites
Spektrum an behandlungsrelevanten Themen (Studien 1 und 2), und stellt in der dritten Studie Patien-
ten, welche gar keine antipsychotische Medikation mehr haben, ins Zentrum (Studie 3). Alle drei Studien
gründen auf den Daten der EUFEST-Studie, einer randomisierten kontrollierten Studie welche Antipsy-
chotika der ersten und zweiten Generation in der Behandlung von Patienten mit einer ersten Episode
der Schizophrenie vergleicht. EUFEST umfasste insgesamt 498 Studienteilnehmende, welche in 13 Be-
handlungszentren aus verschiedenen Europäischen Ländern und Israel rekrutiert wurden. Nach einem
Erstinterview wurden die Teilnehmenden über 12 Monate weiter befragt. Die longitudinale Datenstruktur
ermöglichte es, LCGA (Latent Class Growth Analysis) einzusetzen, welche verschiedene Verlaufsgruppen
bezüglich eines Outcome-Masses identifizieren kann. Zusätzlich wurden die Cox-Regression und Struk-
turgleichungsmodelle eingesetzt. Aus den drei Studien resultierten verschiedene interessante Befunde.
Unter anderem konnte in einer Studie gezeigt werden, dass vor allem soziale unerfüllte Behandlungs-
bedürfnisse über 12 Monate hinweg fortbestanden, und dass diese oft nicht behandelt werden konnten.
Vor allem unerfüllte Behandlungsbedürfnisse die über die Behandlungszeit hinweg verschwanden – nicht
jene die behandelt wurden – waren mit einer höheren Lebensqualität am Ende der Studie assoziiert.
Zudem gab es Hinweise, dass die Entscheidung, ob antipsychotische Medikation abgesetzt werden sollte,
kaum durch klare Regeln begründet war. Diese Befunde können dazu beitragen, die Behandlung der
Erst-Episode-Schizophrenie zu verbessern, und liefern Ideen für zukünftige Forschungsprojekte. Die Dis-
sertation schilesst mit einer kritischen Diskussion des Konzeptes der Behandlungsbedürfnisse, dem Wert
von Sekundäranalysen, und der Generalisierbarkeit der Resultate.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-164417
Dissertation
Published Version
Originally published at:
Landolt, Karin. Treatment needs in first-episode schizophrenia : some additional perspectives. 2015,
University of Zurich, Faculty of Arts.
2
	  Treatment Needs in First-Episode Schizophrenia: Some 
Additional Perspectives 
 
Thesis (cumulative thesis) 
presented to the Faculty of Arts 
of  
the University of Zurich  
for the Degree of Doctor of Philosophy 
 
 
by Karin Landolt 
of Rafz ZH 
 
 
 
Accepted in the fall semester 2012 on the 
recommendation of Prof. Dr. med. Dipl.-Psych. Wulf Rössler  
and PD Dr. Vladeta Ajdacic-Gross 
 
 
 
 
Zürich, 2015 
 
 
	   	   	   II	  
Preface 
 
This dissertation relies on data from the EUFEST-Trial conducted by the EUFEST 
Study Group. I thank the members of this group, the therapists and other staff 
involved in the study, and all the patients who took part in the trial, for their 
engagement and the permission for using the data. I thank the co-authors for their 
contributions to the papers, namely Eske Derks for her competent methodological 
support and Tom Burns for his inputs. My special thanks go to Wulf Rössler for 
offering me the possibility to write this dissertation and for his support, and to Vladeta 
Ajdacic-Gross for his engaged and patient teaching of the craft of scientific work. Last 
but not least I thank my family and my friends and colleagues who supported me 
during the process of writing this dissertation. 
	   	   	   III	  
 
Abstract 
 
The three studies summarised in this cumulative dissertation deal with first-episode 
schizophrenia. The first episode is an especially sensitive moment shaping the 
course of the illness. Therefore, research on this phase is important. Treatment 
during the first episode should target the psychotic symptoms efficiently, but should 
also be as less invasive as possible. As antipsychotic medication mostly fulfils the 
first criterion, but less often the second criterion, it is legitimate to focus on treatments 
that provide relief from symptoms and eventually alternatives to continuous 
medication. This dissertation focuses on treatment needs (Studies 1 and 2), which 
encompass a broader spectrum of topics apart from medication, and deals with 
patients who stopped any antipsychotic medication (Study 3). All three studies were 
conducted using data from the EUFEST-Trial, a randomised controlled trial 
comparing first- versus second-generation antipsychotics in the treatment of first-
episode schizophrenia. The trial encompassed in total 498 participants recruited in 
13 mental health centres from different European countries and Israel. After a 
baseline interview, as many participants as possible were followed-up for 12 months. 
The longitudinal structure of the data allowed for using Latent Class Growth Analysis 
(LCGA), which identifies groups of persons with different courses on one outcome 
measure. Additionally, cox-regression and structural equation modelling were 
implemented. Many different findings emerged from the three studies. Among other 
things one study showed that especially unmet social needs persisted over the 12 
months, and were often in danger of not being addressed adequately. Especially 
unmet needs that disappeared – instead of being met – were associated with a 
higher quality of life at follow-up. Moreover, there were hints that the decision 
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whether to continue with antipsychotic medication or not was not guided by clear 
rules, but rather by attitudes, local use, and “rules of thumb”. All those findings might 
help to improve treatment of first-episode schizophrenia, and provide ideas for further 
research. The dissertation closes with a critical discussion of the concept of 
treatment needs, the value of secondary analyses, and the generalisability of the 
results. 
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Zusammenfassung 
 
Die vorliegende kumulative Dissertation fasst drei Studien zur ersten Episode der 
Schizophrenie zusammen. In der ersten manifesten schizophrenen Episode kann der 
Verlauf der Erkrankung positiv oder negativ beeinflusst werden, was Forschung über 
diese Phase besonders wichtig macht. Die professionelle Behandlung sollte in der 
ersten Episode sowohl auf die Reduktion der psychotischen Symptome abzielen, als 
auch so wenig invasiv wie möglich gestaltet sein. Antipsychotische Medikation wirkt 
wohl antisymptomatisch, erfüllt aber das zweite Kriterium der Nicht-Invasivität 
weniger deutlich. Deshalb ist es legitim, nach Behandlungsmodalitäten zu suchen 
welche Entlastung von Symptomen und gleichzeitig möglicherweise Alternativen zur 
kontinuierlichen antipsychotischen Medikation bieten. 
Diese Dissertation diskutiert Behandlungsbedürfnisse der Patienten, und somit ein 
breites Spektrum an behandlungsrelevanten Themen (Studien 1 und 2), und stellt in 
der dritten Studie Patienten, welche gar keine antipsychotische Medikation mehr 
haben, ins Zentrum (Studie 3). 
Alle drei Studien gründen auf den Daten der EUFEST-Studie, einer randomisierten 
kontrollierten Studie welche Antipsychotika der ersten und zweiten Generation in der 
Behandlung von Patienten mit einer ersten Episode der Schizophrenie vergleicht. 
EUFEST umfasste insgesamt 498 Studienteilnehmende, welche in 13 
Behandlungszentren aus verschiedenen Europäischen Ländern und Israel rekrutiert 
wurden. Nach einem Erstinterview wurden die Teilnehmenden über 12 Monate weiter 
befragt. Die longitudinale Datenstruktur ermöglichte es, LCGA (Latent Class Growth 
Analysis) einzusetzen, welche verschiedene Verlaufsgruppen bezüglich eines 
Outcome-Masses identifizieren kann. Zusätzlich wurden die Cox-Regression und 
Strukturgleichungsmodelle eingesetzt.  
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Aus den drei Studien resultierten verschiedene interessante Befunde. Unter anderem 
konnte in einer Studie gezeigt werden, dass vor allem soziale unerfüllte 
Behandlungsbedürfnisse über 12 Monate hinweg fortbestanden, und dass diese oft 
nicht behandelt werden konnten. Vor allem unerfüllte Behandlungsbedürfnisse die 
über die Behandlungszeit hinweg verschwanden – nicht jene die behandelt wurden – 
waren mit einer höheren Lebensqualität am Ende der Studie assoziiert. Zudem gab 
es Hinweise, dass die Entscheidung, ob antipsychotische Medikation abgesetzt 
werden sollte, kaum durch klare Regeln begründet war. Diese Befunde können dazu 
beitragen, die Behandlung der Erst-Episode-Schizophrenie zu verbessern, und 
liefern Ideen für zukünftige Forschungsprojekte. Die Dissertation schilesst mit einer 
kritischen Diskussion des Konzeptes der Behandlungsbedürfnisse, dem Wert von 
Sekundäranalysen, und der Generalisierbarkeit der Resultate. 
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1 Introduction 
 
Schizophrenia is one of the disorders that result in a very high burden for the persons 
who are affected with. There is no possibility to heal schizophrenia up to now, even 
though effective treatments are available. Therefore, research which helps to 
understand the disorder, to develop adequate treatment methods, and to support 
patients to cope with the symptoms, is still urgently needed. Every little step in 
direction of an understanding of schizophrenia is in fact a huge advantage. The first 
episode of schizophrenia is an especially sensitive moment and shapes the course of 
the illness, since the experiences patients have with the treating therapists and 
institutions can be formative for their readiness to adhere to treatment in the future. In 
the following, some treatment concepts are summarized. For a comprehensive 
discussion of the topic, the interested reader is referred to the introductions of the 
three studies and to the large body of published research articles. 
 
2.1 First-episode schizophrenia, treatment and treatment needs 
 
2.1.1 Definition 
First-episode schizophrenia is defined as the first occurrence of an episode of illness 
that fulfils the diagnostic criteria of schizophrenia spectrum disorder according to the 
DSM-IV or the ICD-10 diagnostic manual. This definition does not take into account 
the possible vagueness of boundaries at the ends of the schizophrenia spectrum; 
and has to be differentiated from first episode psychosis (1). The results of studies on 
first-episode schizophrenia can differ because of inclusion criteria. In this study, first-
episode schizophrenia is defined as the first episode of DSM-IV diagnosis of 
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schizophrenia, schizoaffective disorder or schizophreniform disorder (2). As 
schizophreniform and schizoaffective disorders have better prognoses than 
schizophrenia, the inclusion of those diagnoses might result in better outcomes in 
this sample compared with samples reduced to schizophrenia alone (3, 4). The 
diagnosis of schizophrenia includes a time criteria specifying that signs of the illness 
must be present for at least 6 months. Therefore, a first episode can only be 
diagnosed after some time has passed. Even then, first-episode samples show 
higher rates of response to antipsychotic medication and remission than samples 
with an established illness (2). Among the first-episode patients, there are obviously 
more cases with a better prognosis who might benefit from different treatment 
strategies.  
 
Before the exacerbation of a first episode of schizophrenia, a more or less 
pronounced prodromal phase occurs in most of the cases. Any intervention during 
this prodromal phase in turn influences the course of illness. Thus, systematic early 
intervention might result in more cases who do well with minimal invasive treatment 
options (5).  
 
2.1.2 Treatment of first-episode schizophrenia 
Antipsychotic medication is the recommended treatment method in any phase of the 
established illness (6, 7). But additionally, to address psychosocial functioning is 
considered (8) which is supposed to hinder deterioration in such functioning during 
the later course of the illness (9). In first-episode schizophrenia, there are some 
arguments against default medication: As medication often provokes severe side 
effects (10-14), patient’s adherence is impaired and their compliance with treatment 
affected. Compliance and adherence is important for the later course of the illness 
	  	   3	  
(15, 16). Moreover, studies constantly identify a proportion of patients who remit 
without medication (17, 18); their number is strongly dependent on the definition of 
relapse (19). Age, social competence, prognosis and number of diagnostic symptoms 
(18, 20) are possible predictors of response without antipsychotic medication, but 
results of different studies are inconsistent (20).  
 
As there are patients who remit without antipsychotic medication, criteria are needed 
to decide when to continue or to discontinue medication (17). Thus, the challenge is 
to treat the psychotic episode efficiently, but at the same time, to use a treatment 
method that is as less invasive as possible. This legitimates the focus on treatment 
alternatives to antipsychotic medication. 
 
2.2 Treatment needs 
 
2.2.1 Definition 
In general, the concept of treatment need is determined by recovery from illness. 
From the perspective of severe mental illnesses, this is reduced to the need of 
interventions that enhance quality of life and help the patient to cope with the 
symptoms and the consequences of being severely mentally ill. In this context, 
treatment needs are defined as prerequisites for maintaining or restoring an 
acceptable level of social independence and quality of life (21).  
 
2.2.2 Psychological interventions 
Next to medication targeted to reduce psychotic symptoms, patients suffering from 
schizophrenia have widespread treatment needs. Psychological interventions are an 
important component of treatment of early psychosis, even though final scientific 
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proof for the efficacy of those interventions is still needed (22). Psychological 
interventions are useful to address substance use (23), activate protective factors, or 
are targeted to specific symptoms or deficits (24). Cognitive approaches might 
improve functioning (25), among other things. Last but not least there is the need to 
keep physical health: Persons suffering from schizophrenia might suffer from 
inequalities in healthcare provision which in turn influences mortality rates (26).  	  
3 Aims 
 
The general aim of the secondary analyses was to add to the knowledge about 
treatment needs in first-episode schizophrenia using a large data set – which proved 
to be very useful for the discussion on first- and second-generation antipsychotics 
(27) - by focusing on treatment needs apart from antipsychotic medication.  
 
The main specific aims were: 
1. To gain broader insight into the longitudinal interrelation between quality of 
life, unmet needs, symptom severity, clinical status, and functioning by 
differentiating needs that are being met and needs that disappear during 
treatment. 
2. To identify the course of needs over a 12-month period in first-episode 
patients compared with chronic schizophrenia patients. 
3. To identify clusters of patients with different trajectories of unmet needs. 
4. To determine variables that are associated with the trajectories of unmet 
needs. 
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5. To find out more about patients suffering from first episode schizophrenia but 
not using antipsychotic medication continuously. 
6.  To examine whether any useful information at all could be gained from such 
trials regarding the topic of non-continuous antipsychotic medication. 
 
4 Implementation 	  
4.1 Data and Methods 
 
4.1.1 The EUFEST-Trial 
All analyses were conducted using data from the EUFEST-Trial (2, 27), a 
randomised controlled trial comparing first- versus second-generation antipsychotics 
in the treatment of first-episode schizophrenia. The trial encompassed in total 498 
participants recruited in 13 mental health centres from different European countries 
and Israel. Outcome of the core study was discontinuation of study drug. But all 
patients who did not drop out of the study were followed up with in total 9 
assessments encompassing one year. A wide range of information was assessed at 
different visits, which allowed for studying other themes than first- versus second-
generation antipsychotic medication using the EUFEST data. The three studies 
summarised in this dissertation focused on treatment needs and the question of 
antipsychotic-free treatment.  
 
4.1.2 Treatment needs 
Treatment needs are often assessed using questionnaires. This study uses the CAN 
(Camberwell Assessment of Need; (28)), inquiring about 22 potentially problematic 
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areas of living and differentiating among met need (patient has a need and this need 
is met by treatment), unmet need (specific need that is not met by treatment), and no 
need (patient does not have a need in this area of living). Using a questionnaire has 
the advance of yielding reliable data, also when the interviewers are not clinicians or 
extensively trained. But it is possible that individual needs, or needs that are 
especially important for first-episode patients, are missed by the a priori defined 
questions. 
4.2 Summaries of the studies  
 
4.2.1 Study 1 
The first study aimed to identify the course of unmet needs by patients with a first 
episode of schizophrenia and to determine associated variables.  
Baseline assessments in the EUFEST trial as well as follow-up interviews at 6 and 12 
months were investigated. Latent class growth analysis was used to identify patient 
groups based on individual differences in the development of unmet needs. 
Multinomial logistic regression determined the predictors of group membership.  
Four classes were identified. Three differed in their baseline levels of unmet needs 
while the fourth had a marked decrease in such needs. Main predictors of class 
membership were prognosis and depression at baseline, and the quality of life and 
psychosocial intervention at follow-up. Depression at follow up did not vary among 
classes.  
Subtypes of patients with different courses of unmet needs were identified. Needs 
concerning social relationships were particularly persistent in subtypes who remained 
high in their unmet needs and who lacked additional psychosocial treatment. 
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4.2.2 Study 2 
The interrelation between needs for care and quality of life has been described and 
replicated by several studies. The second study aimed to add to the understanding of 
longitudinal interrelations between needs for care, quality of life, and other outcome 
measures by analyzing a sample of patients at the onset of schizophrenia.  
This study relied on the first (baseline) and the last assessment (12 months after 
baseline) of the EUFEST-Trial. Predictors of quality of life were determined using 
regression analyses. The complex longitudinal interrelations between baseline and 
outcome measures were tested with structural equation models. 
There was a marked improvement in the total sample on all psychosocial and 
psychopathological measures. Needs were not definitively confirmed as a predictor 
of subsequent quality of life. Unmet needs changing to no needs were a stronger 
predictor of quality of life than unmet needs changing to met needs. 
This study suggests that when studying quality of life and needs for treatment, it is 
crucial to differentiate whether unmet needs disappear or whether they were met, as 
the former has a stronger impact on quality of life. 
 
4.2.3 Study 3 
This study aimed to describe patients suffering from first-episode schizophrenia who 
stopped taking any antipsychotic medication, and to gain information on the 
predictors of successful discontinuation. Since trials comparing placebo or 
psychosocial intervention against antipsychotic medication raise ethical concerns, 
secondary analyses are particularly important in this context. 
We investigated data from the European First Episode Schizophrenia Trial 
(EUFEST). In a first analysis, global correlates of discontinuing antipsychotic 
medication were identified using Cox-regression. In the second study, logistic 
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regression was used to determine variables associated with those patients who had 
stopped taking antipsychotic medication and had a favorable outcome, i.e., 
successful discontinuation. 
Cox-regression revealed that more patients from Western European countries and 
Israel stopped antipsychotic medication than from Central and Eastern European 
countries, that relapse was associated with discontinuing, and that those persons 
had lower compliance and higher quality of life. Predictors of successful 
discontinuation differed with the outcome definition used. When a good outcome was 
defined as having no relapse, successful discontinuers were more often from 
Western European countries and Israel, had more often an abnormal ECG and 
higher baseline depression scores. When a good outcome was defined as having no 
relapse and reaching symptomatic remission, successful discontinuers had a better 
prognosis and better baseline social integration. 
Initial depression, prognosis and social integration played an important role in 
predicting successful discontinuation. As decisions of therapists and patients 
regarding antipsychotic medication seemed to be also influenced by local treatment 
practice and factors other than clinical status, further studies are needed to identify 
and discuss basic principles of decision making. 
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5 Integration of results 
 
These three studies addressed the broad spectrum of treatment needs in first-
episode schizophrenia and resulted in some findings that should be considered when 
attempting to improve the treatment of first-episode schizophrenia and in future 
research. The first study indicated that especially unmet social needs seem in danger 
of not being addressed adequately, which might impair psychosocial functioning of 
patients in the long-term. The second study moderates the finding that meeting need 
by treatment enhances outcome quality of life (29, 30). It shows that the 
disappearance of unmet needs – not meeting them per se – is important for a better 
quality of life after 12 months. The third study confirms that treatment without 
antipsychotic medication is possible for at least some patients. But it also indicated 
that the decision for treatment without antipsychotic medication seems to be last but 
not least a question of attitude of therapists and patients. 
 
5.1 Is treatment need a meaningful concept for research and treatment 
guiding in first-episode schizophrenia? 
 
There are arguments that question the usefulness of treatment needs as a 
meaningful concept in research and treatment of schizophrenia (31). Regarding first-
episode schizophrenia, there is no discussion on this topic up to now. The following 
pro arguments can be inferred from the present studies: First of all, the concept of 
need accounted for the wants and wishes of the individual patient. This is a pro 
argument because it leads the focus not only on medication but also on other areas 
of patient’s life, e.g. social needs, which might be of importance for at least some 
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patients. As needs can differ from patient to patient, research on needs should 
always discern different groups of patients with different combinations of needs. 
Keeping the diversity of needs in mind will also lead idea finding in research.  
 
On the more negative argumentative side are the inconsistent interrelations of 
treatment needs with other well-established outcome measures in first-episode 
schizophrenia, especially psychopathology and quality of life. On the one hand, this 
could mean that treatment need measures another dimension of outcome than the 
other measures. But, on the other hand, it might be possible that the concept of need 
is not a valid outcome measure in first episode schizophrenia. Last but not least, the 
difference between disappearing needs and needs that are being met remained 
unclear. Here, further research is needed to answer those questions and to enable 
an unequivocal decision regarding the benefit of measuring treatment need in first-
episode schizophrenia. 
 
5.2 What can be learned from secondary analyses of RCT’s on antipsychotic 
medication? 
 
The secondary analyses of the EUFEST-Study data yielded findings that provided 
interesting ideas for research and treatment. But as secondary analyses are 
explorative by design, and findings from such studies always need confirmation by 
experimental research, the question remains whether the results are important 
enough to legitimate the amount of work such analyses afford.  
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Some pro arguments are the following: 
• First, it was also a large amount of work to collect the data of the EUFEST-
Study. The EUFEST-Trial encompassed a remarkable, very uniform sample of 
first-episode patients treated in different European mental health centres, and 
used a broad collection of measures of different aspects of the illness. 
Analysing as many of those concepts assessed, resulting in a broad spectrum 
of findings, values the participant’s effort by making the best of it.  
• Another topic is whether the trial’s focus on medication limits the validity of 
results not concerning medication. On the one hand it does, because the 
study has been designed to test this topic, and when studying other questions 
one is often confronted with limited capacity of the study design. On the other 
hand, other themes are not subjected to biases generated by participating in a 
(non-double-blinded) study. Moreover, the researcher is not prejudiced 
regarding the results of secondary analyses because he is in the debt of the 
sponsors who funded the study. 
 
5.3 Outlook 
 
An important conclusion from the three secondary analyses is that treatment needs is 
a very complex outcome measure with manifold associations and equivocal 
interrelations with psychopathology and standard antipsychotic medication. 
Moreover, as two of the analyses showed, to identify patients with different courses 
of outcomes is a very useful procedure in research that aims to generate hypotheses. 
To close with, my most important point is to encourage research on the whole 
spectrum of treatment needs and treatment options in first-episode schizophrenia, as 
this is, to my opinion, a good way to support practitioners to be responsive to the 
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individual person of the patient, and to find the treatment mode which supports 
him/her best on her/his way towards health.  
 
5.4 Evaluation of the relevance of the findings 
 
Any relevance of findings depends strongly on the generalizability of the results. The 
EUFEST-Trial collected a large sample of patients coming from different mental 
health centres in Europe and Israel. The sample is not representative concerning the 
selection of centres and patients. Therefore, it gives a good overview over the 
situation in Europe, but strictly speaking, results cannot be generalized to all first-
episode patients. Another critical point is the definition of first-episode schizophrenia. 
As described in paragraph 1.1.1, the definition is not unequivocal. Moreover, patients 
were included when the onset of positive symptoms was no longer than two years 
ago. Within two years, it is possible that more than one episode of schizophrenia has 
occurred. Despite the large total sample, each of the three analyses struggled with 
marginal sample sizes. Therefore, statistical models were not very stable, and it is 
possible that the effects of some predictors were over- and effects of others 
underestimated. The results clearly need to be confirmed by other studies. 
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Abstract 
 
Background: 
This study aimed to identify the course of unmet needs by patients with a first 
episode of schizophrenia and to determine associated variables. 
 
Methods: 
We investigated baseline assessments in the EUFEST trial as well as follow-up 
interviews at 6 and 12 months. Latent class growth analysis was used to identify 
patient groups based on individual differences in the development of unmet needs. 
Multinomial logistic regression determined the predictors of group membership. 
 
Results: 
Four classes were identified. Three differed in their baseline levels of unmet needs 
while the fourth had a marked decrease in such needs. Main predictors of class 
membership were prognosis and depression at baseline, and the quality of life and 
psychosocial intervention at follow-up. Depression at follow up did not vary among 
classes. 
 
Conclusions: 
We identified subtypes of patients with different courses of unmet needs. Prognosis 
of clinical improvement was a better predictor for the decline in unmet needs than 
was psychopathology. Needs concerning social relationships were particularly 
persistent in subtypes who remained high in their unmet needs and who lacked 
additional psychosocial treatment. 
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Abstract  
 
Background: 
The interrelation between needs for care and quality of life has been described and 
replicated by several studies. The present work aims to add to the understanding of 
longitudinal interrelations between needs for care, quality of life, and other outcome 
measures by analyzing a sample of patients at the onset of schizophrenia. 
 
Methods: 
This study relied on data from the EUFEST trial, designed to compare first- and 
second-generation antipsychotics during one year. At baseline, 498 patients have 
been included. The first (baseline) and the last assessment (12 months after 
baseline) were used for the analyses. Predictors of quality of life were determined 
using regression analyses. We tested the complex longitudinal interrelations between 
baseline and outcome measures with structural equation models. 
 
Results: 
Unmet needs were not definitively confirmed as a predictor of subsequent quality of 
life, unless unmet needs changing to no needs were separated from unmet needs 
changing to met needs. Each unmet need that changed to no need enhanced quality 
of life (mean score 1 - 7) by 0.136 scale points. 
 
Conclusions: 
This study suggests that when studying quality of life and needs for treatment, it is 
crucial to differentiate whether unmet needs disappeared or whether they were met, 
as the former has a stronger impact on quality of life.
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III Study 3: Discontinuation of antipsychotic medication: Predictors 
and outcomes in the EUFEST trial	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Abstract 
 
Background: 
This study aimed to describe patients suffering from first-episode schizophrenia who 
stopped taking any antipsychotic medication, and to gain information on the 
predictors of successful discontinuation. Since trials comparing placebo or 
psychosocial intervention against antipsychotic medication raise ethical concerns, 
secondary analyses are particularly important in this context. 
 
Methods: 
We investigated data from the European First Episode Schizophrenia Trial 
(EUFEST). In a first analysis, global correlates of discontinuing antipsychotic 
medication were identified using Cox-regression. In the second study, logistic 
regression was used to determine variables associated with those patients who had 
stopped taking antipsychotic medication and had a favorable outcome, i.e., 
successful discontinuation. 
 
Results: 
Cox-regression revealed that more patients from Western European countries and 
Israel stopped antipsychotic medication than from Central and Eastern European 
countries, that relapse was associated with discontinuing, and that those persons 
had lower compliance and higher quality of life. Predictors of successful 
discontinuation differed with the outcome definition used. When a good outcome was 
defined as having no relapse, successful discontinuers were more often from 
Western European countries and Israel, had more often an abnormal ECG and 
higher baseline depression scores. When a good outcome was defined as having no 
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relapse and reaching symptomatic remission, successful discontinuers had a better 
prognosis and better baseline social integration. 
 
Conclusions: 
Initial depression, prognosis and social integration played an important role in 
predicting successful discontinuation. As decisions of therapists and patients 
regarding antipsychotic medication seemed to be also influenced by local treatment 
practice and factors other than clinical status, further studies are needed to identify 
and discuss basic principles of decision making. 
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Introduction 
 
Antipsychotic medication is the state of the art in treating first-episode schizophrenia 
(1). However, the potentially serious side effects of first- and second-generation 
antipsychotics (2-6), and findings identifying a small proportion of first-episode 
patients who do well with psychosocial intervention alone (7) serve as a basis for a 
discussion of the necessity of antipsychotic medication in these patients (for a 
comprehensive overview see (8)). In the long-term, about one third of patients may 
not need antipsychotics continuously (9). Moreover, adherence in first-episode 
patients is poor (10-12). Therefore, strategies to reduce medication without putting 
the benefits of antipsychotics at stake have been suggested. Some authors 
introduced approaches that include - more or less scheduled - gaps of days or weeks 
where no antipsychotic drugs are given (e.g. non-continuous dosing, “drug holidays”) 
(13). Non-continuous antipsychotic dosing is supposed to maintain antipsychotic 
efficacy and decrease the risk of side effects compared with continuous dosing (13). 
But for most of the patients, with longer gaps relapse- and rehospitalisation rates 
increase (14). Other authors advocate alternative treatment strategies for at least a 
subgroup of patients who show an antipsychotic-free treatment response (8, 15-17). 
For this approach, it would be of utmost importance to be able to identify patients 
with a high likelihood of an antipsychotic-free treatment response as early as 
possible. This might be possible by a stepwise refinement of predictive knowledge 
from successive research studies. Firstly, a thorough review of existing studies 
dealing with the topic and additional secondary analyses of existing data sets are 
needed. Once reasonably reliable predictive factors have been identified, 
randomized controlled studies should be considered. The same holds true when 
planning to introduce medication gaps (non-continuous dosing). Unfortunately, 
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predictors of successful discontinuation are largely unknown (14), as are predictors 
of an entirely antipsychotic-free positive treatment response (8). This study aimed to 
study predictors of successful discontinuation (i.e. having a favourable outcome 
despite not continuing to take antipsychotic medication), and to add to the knowledge 
on the circumstances associated with the discontinuation of antipsychotic medication 
in first-episode psychosis. 
 
As cited above, there are relevant arguments for the potential benefits and feasibility 
of non-continuous dosing and, for certain patients, treatment without antipsychotic 
medication. But studies that address these topics are rare because they are ethically 
critical (7, 18, 19). Since medication is necessary in most instances, one would not 
risk withholding antipsychotic medication. Naturalistic studies and secondary 
analyses of antipsychotic medication trials may shed more light on this issue. The 
European First Episode Schizophrenia Trial (EUFEST) is well suited for such 
secondary analyses because all patients were started on antipsychotic medication at 
baseline, and because patients were followed up even if they did not continue to take 
study medication. The study was designed as a pragmatic clinical trial in order to 
reflect everyday clinical practice as much as possible. In addition, EUFEST 
comprises a remarkably large and homogenous sample of patients (20). 
 
The aim of the present paper is to provide more information about patients suffering 
from first-episode schizophrenia who discontinue antipsychotic medication. Study 1 
attempts to identify variables associated with discontinuing antipsychotic medication 
and study 2 aims to identify predictors of successful discontinuation. 
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Methods 
 
Database 
This study is based on data from the European First Episode Schizophrenia Trial 
(EUFEST) (20, 21), in which four second-generation antipsychotics (amisulpride, 
olanzapine, quetiapine and ziprasidone) were compared to treatment with a low dose 
of haloperidol (21). Details of the study design have been previously reported (20, 
21). The main outcome measure was loss of retention (LOR) in the study after one 
year or, in other words, the comparative proportion of patients who stayed on the 
antipsychotics they were initially randomized to. Patients who met LOR criteria were 
nevertheless followed up over the one year observation period and eventual switches 
to other antipsychotics were recorded. In contrast to the primary EUFEST report, the 
focus of the present paper is on any antipsychotic, not on the original study 
medication, and the outcome measure is the discontinuation of all antipsychotic 
medications. From the various additional outcome measures assessed in EUFEST, 
psychosocial and psychiatric symptom measures, electrocardiogram (ECG), 
functioning, quality of life, and Clinical Global Impression were used for the purpose 
of the present analyses (see below). 
 
Sample 
Fifty mental health centres in 13 European countries and Israel were selected for 
participation. Altogether, 1047 patients were screened for eligibility between 
December 2002 and January 2006. Inclusion criteria were ages 18 to 40 years; a 
DSM-IV diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective 
disorder; onset of positive symptoms dating back two years at most; use of 
antipsychotic drugs for at most two weeks in the previous year not more than total of 
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six weeks at any time; and no known intolerance or contraindication for one of the 
study drugs. Diagnoses were confirmed by the International Neuropsychiatric 
Interview (MINI plus) (22). In all, 498 patients gave informed consent and were 
randomly assigned to five treatment groups. The study protocol was evaluated by 
local ethics committees or review boards according to country-specific laws. 
 
Attrition rates 
Of the 1047 patients initially assessed for eligibility, 498 were included and 
randomized to one of the study drugs. 291 (58.4%) continued and 207 (41.6%) 
discontinued the study drug. Of those who continued, 198 (68.0%) patients 
completed the 12-month follow-up, 194 of which could be included in the present 
analyses. Of those who discontinued study drug, 144 (69.6%) completed the full 
follow-up, 13 of them were excluded from the analyses because of missing data. The 
80 patients who switched to or added another antipsychotic agent, or changed dose 
of study medication, were added to the 194 patients who continued study drug, 
together building the sample of 274 “continuers” (Figure 1). 51 patients were 
identified who discontinued any antipsychotic medication, building the sample of 
“discontinuers” (Figure 1). The sample used in the present analyses thus comprised 
325 patients (274 “continuers” and 51 “discontinuers”) (Figure 1). 
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Figure 1: Flow chart illustrating the selection of the sample of the EUFEST-Trial and 
the sample used for the present analyses. For studies 1 and 2, the subsamples in the 
shaded boxes were used. 
 
Study 1 
Study 1 is close to the main EUFEST-paper (21) regarding the methods used. The 
difference is that the present study aimed to identify the correlates of stopping any 
antipsychotic medication, while the primary EUFEST-paper focused on the 
antipsychotic medication patients were randomly assigned to at study baseline. To 
this end, patients who stopped any antipsychotic medication and did not 
recommence during the 12-months trial duration were identified. All patients who 
discontinued medication had several follow-up interviews (Visits 2-9), analogous to 
the patients who continued on study medication. All medication use was assessed at 
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each visit by recording the dates of beginning and ending. This information allowed 
for calculating the exact time-span a patient spent on treatment, which was used as a 
dependent variable in a Cox-regression model. Cox-regression uses the hazard-
function to examine the survival time depending on external influences. Therein it is 
possible to define time-dependent covariates. All independent variables listed below 
(see “independent variables”) were used in this model. Repeatedly measured 
independent variables were integrated in the model as segmented time-dependent 
covariates. Missing values on independent variables were replaced by the mean of 
the two values of the previous and following visit. When two or more consecutive 
values were missing, no replacement was made, and the respective cases were 
excluded for study 1. This applied to nine patients of the basic sample (N = 325). The 
“backstep Wald” procedure was used to identify most relevant covariates 
(independent variables). Cox-regression models were calculated with SPSS (PASW 
Statistics 18.0). 
 
Study 2 
In the second study, we were interested in the characteristics of patients who were 
successful “discontinuers”. Two definitions of success, i.e. a favourable outcome, 
were used: A wider one, having had no clinical relapse, and a narrower one, being a 
combination of no relapse and symptomatic remission, as defined by Andreasen et 
al. (23). The group of successful discontinuers was compared a) to the whole rest of 
the basic sample of 325, thus identifying successful discontinuers from all other 
patients, and b) to the patients who stopped antipsychotic medication and did not 
have a favourable outcome, thus differentiating between successful and 
unsuccessful discontinuers. Logistic regression was used for all the comparisons 
described above. Using bivariate regressions, associated baseline variables were 
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selected from the predictors described below (see section “independent variables”) 
on the basis of their significance (P<0.05). All bivariately significant variables were 
entered into one regression model, and the strongest predictors were determined 
with the FSTEP procedure (several predictors) or the ENTER procedure (only one 
predictor) using SPSS (PASW Statistics 18.0). 
 
Independent Variables 
Several measures were selected as predictors: gender, age, country, years of 
education, electrocardiogram (ECG) (ECG is relevant because many antipsychotics 
have cardiac side effects, thus patients with an abnormal baseline ECG have fewer 
possibilities to switch to other antipsychotic agents, e.g. should avoid typical 
antipsychotics and ziprasidone), prognosis (a six-point scale ranging from 1=best to 
6=bad), remission (PANSS items according to (23), see also (24)), relapses, 
compliance (Hayward scale (25)), positive and negative symptoms (PANSS, Positive 
And Negative Syndrome Scale (26)), anxiety (from the PANSS), depression (CDSS, 
Calgary Depression Scale for Schizophrenia (27)), GAF (Global Assessment of 
Functioning (28)), CGI (Clinical Global Impression (29)), unmet needs (CAN, (30)), 
quality of life (MANSA, Manchester Short Assessment of Quality of Life (31)), and a 
proxy for social integration at baseline using items from the MANSA (satisfaction with 
friendships, family, sex life, cohabitants) and the CAN (met or unmet need regarding 
company, intimate relationship, sexual expression).  
For study 2, a combined outcome measure was determined via two criteria:  
a) having had any relapse during the study (yes/no), and b) symptomatic remission at 
12-months follow-up (PANSS items according to Andreasen et al. (23), see also 
(24)). 
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The 14 participating countries were clustered into two regions: Western European 
(The Netherlands, Belgium, France, Switzerland, Austria, Germany, Sweden, Spain, 
and Italy) and Eastern and Central European (Bulgaria, Poland, Romania, and Czech 
Republic). Because only a few patients were from Israel, that country was added to 
the Western European category to control for cell sizes and confidence intervals.  
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Results 
 
Study 1 
 
Study 1 focused on the correlates of discontinuing any antipsychotic medication. Of 
the 325 patients included in the basic sample, 51 discontinued antipsychotic 
medication completely, 80 switched from the original study medication to another 
antipsychotic, and 194 did not change the drug they were randomised to at baseline 
(Figure 1). Time until complete discontinuation of the 51 patients was used as the 
dependent variable in the Cox-regression. Patients who continued the study drug or 
switched to another agent were defined as censored (N = 80 + 194 = 273, see Figure 
1). Significant correlates of stopping antipsychotic medication were: Coming from 
Western Europe / Israel, lower compliance, relapse, and a better quality of life. 
Variables in the final model that were not significant were abnormal ECG and better 
prognosis (Table 1). A cross-tabulation revealed that abnormal ECG was only 
associated with stopping in Eastern- and Central-European countries (results not 
shown but available on request). 
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Table 1: Results of Cox-Regression. Dependent variable = duration of phase with 
any antipsychotic medication. Displayed are predictors included in step 13 using the 
backstep method with the Wald-Criteria (N = 316, N(event) = 50, N(censored) = 266; 
PIN = 0.05, POUT = 0.10). 
 B SE Wald Df P Exp(B) 
Region (WE = 1 EE = -1) 0.399 0.152 6.894 1 0.009 1.491 
Compliance (high = better) -0.436 0.087 25.319 1 0.000 0.647 
ECG V1 (1 = norm, -1 = abn) -0.301 0.181 2.776 1 0.096 0.740 
Prognosis V1 (high = worse) -0.212 0.120 3.127 1 0.077 0.809 
Relapse (1 = no yes = -1) -0.482 0.229 4.427 1 0.035 0.618 
Quality of life 0.390 0.178 4.780 1 0.029 1.477 
 
 
Study 2 
 
Relationship between (dis-)continuation of antipsychotics and outcome 
In the second study, we focused on the characteristics of patients who discontinued 
antipsychotic medication and had a favourable outcome, i.e. successful 
“discontinuers”. Of the 51 participants who stopped any antipsychotic drug as defined 
in study 1, 12 (23.5%) had at least one relapse, while 39 (76.5%) had no relapse; 
considering a more stringent definition of outcome (no relapse and symptomatic 
remission), 18 (35.3%) had a good, and 33 (64.7%) not a good outcome (Table 2). 
Table 2 also illustrates the different reference groups used in the analyses of Study 
2. 
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Table 2: Comparison groups used in Study 2. “No medication – good outcome” is the 
target group that was compared to two different reference groups, A and B (rows), 
using two definitions of success (columns). Depicted are numbers of patients in the 
respective cells. 
 
No relapse No relapse AND 
remission 
No medication / good outcome 39 18 
Ref. group A: rest of basic sample 281 304 
Ref. group B: not good outcome, no medication 12 33 
 
 
Outcome in the wider definition did not differ between those who stopped and those 
who did not (Figure 2): Of the participants without antipsychotic medication 
throughout the study, 35.3% had a good outcome, and of those with antipsychotic 
medication 37.6% had a good outcome (Chi-Square Test = 0.097, df = 1, exact two-
sided significance = 0.857). Neither did the more narrow definition: 18.6% of the 
participants with antipsychotic medication had at least one relapse compared to 
23.5% of the “discontinuers” (Chi-Square Test = 0.665, df = 1, exact two-sided 
significance = 0.441). This inconsistency with the results of study 1 is resumed in the 
discussion. 
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Figure 2: Illustrating that patients who stopped antipsychotic medication did not have 
a good outcome less often than those with antipsychotic medication. 
 
Characteristics of successful “discontinuers” 
Table 3a shows logistic regressions using “no relapse”, the wider definition of a good 
outcome. The group of interest were successful discontinuers. They were compared 
to two reference groups: To the rest of the basic sample (Model A), and to patients 
with a relapse despite taking antipsychotics (Model B). 
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Table 3a: Logistic regression models for patients without relapse and who quitted 
antipsychotic medication (N=39): Model A: compared against the rest of the sample 
(N=281). Model B: compared against patients without antipsychotic medication but 
with relapse (N=12). 
Model A*: “no relapse / no antipsychotics” (1) 
vs. “rest of the sample” (0) B SE Wald Df P Exp(B) lCl uCl 
Region (1=WE/I, 0=EE/CE) 1.192 .370 10.360 1 .001 3.293 1.594 6.804 
V1 ECG (1=normal, 0=abnormal) -1.171 .452 6.716 1 .010 .310 .128 .752 
V1 CDSS .070 .034 4.088 1 .043 1.072 1.002 1.147 
Model B**: “no relapse / no antipsychotics” (1) 
vs. “relapse / no antipsychotics” (0) 
B SE Wald Df P Exp(B) lCl uCl 
Years of education -.354 .164 .668 1 .031 .702 .509 .968 
* 88.4% were classified correctly, R-Square: Cox and Snell=0.060, Nagelkerke=0.115. FSTEP entered: region, 
ECG, depression (CDSS). 
** 76.5% were classified correctly, R-Square: Cox & Snell=0.115, Nagelkerke=0.173 (ENTER). 
 
 
Comparing successful discontinuers against other patients, significant baseline 
predictors of no antipsychotics / no relapse were region (more common in Western 
and Central Europe), ECG, and depression (higher baseline scores) (Model A). 
Years of education separated the successful (fewer years of education) from the non-
successful quitters in Model B. 
 
Table 3b summarizes analyses analogous to table 3a, except that a more stringent 
definition of favourable outcome was used (no relapse and symptomatic remission). 
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Table 3b: Logistic regression models for patients with a good outcome and who 
quitted antipsychotic medication (N=18): Model A: compared against the rest of the 
sample (N=304). Model B: compared against patients without antipsychotics and 
without good outcome (N=33). 
Model A*: “outcome+ / no antipsychotics” (1) vs. 
“rest of the sample” (0) B SE Wald Df P Exp(B) lCl uCl 
Prognosis -.535 .251 4.537 1 .033 .586 .358 .958 
Social integration .281 .119 5.612 1 .018 1.324 1.050 1.670 
Model B**: “outcome+ / no antipsychotics” (1) 
vs. “outcome- / no antipsychotics” (0) 
B SE Wald Df P Exp(B) lCl uCl 
Prognosis -1.011 .360 7.887 1 .005 .364 .180 .737 
Social Integration .382 .180 4.521 1 .033 1.465 1.030 2.082 
* 94.4% were classified correctly, R-Square: Cox and Snell=0.041, Nagelkerke=0.116. FSTEP entered: gender, 
prognosis (low = better), social integration, QOL. Gender was bivariately only near significance (p=0.051). 
** 78.4% were classified correctly, R-Square: Cox & Snell=0.256, Nagelkerke=0.352. FSTEP entered: Age, 
gender, years of education, prognosis (low = better), social integration, CGI. 
 
Using the narrower definition of favourable outcome, significant baseline predictors of 
no antipsychotics / no relapse were prognosis (better) and social integration (higher 
baseline scores with both reference groups (Models A, B). 
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Discussion 
 
We examined a sample of patients suffering from first-episode schizophrenia who 
were all taking antipsychotic medication at study entry, with a focus on patients who 
discontinued medication. The large, international sample and the longitudinal study 
design used made it possible to study the characteristics of first episode patients who 
stopped taking antipsychotics and the consequences of discontinuation, on outcome. 
Most surprisingly, we were not able to detect a statistical difference in outcome 
between patients who discontinued medication and those who stayed on 
antipsychotics.  
Patients living in West-European countries or Israel more often stopped taking any 
antipsychotic medication. Other variables significantly associated with stopping 
antipsychotic medication were: low compliance, better quality of life, and having a 
relapse (study 1). Neither psychotic symptoms, nor measures of severity of illness 
and functioning differentiated between patients who stopped and those who 
continued using antipsychotics.  
Predictors of successful discontinuation varied with definition of success: Using a 
wider definition, the predictors of successful discontinuation were region (Western 
Europe/Israel) and ECG, paralleling the predictors of discontinuation in general, and 
a higher baseline level of depression. Successful discontinuers differed from 
unsuccessful ones just by fewer years of education. Using a more stringent definition 
of a good outcome which included remission next to not experiencing a relapse, 
better prognosis and better baseline social integration predicted successful 
discontinuation (study 2).  
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The decision process 
The analyses confirmed the supposition that there were diverse decision-taking 
processes involved the decision to stop antipsychotic medication. The decision could 
be taken by patients alone, in accordance with their therapists, or be initiated by 
therapists. Two observations indicate that those decision rules were not primarily 
driven by criteria related to psychopathology: 
• West-European or Israeli therapists and patients decided more often to 
continue without antipsychotic medication than their counterparts form 
Central- or East-European countries. This indicates that local clinical practice 
is involved in the decision. 
• Patients and/or therapists in Central and East Europe seemed to be more 
likely to discontinue antipsychotics when patients’ ECG was abnormal, 
probably because they feared cardiovascular problems.  
This also illustrates that there is a range of actions regarding the decision whether to 
stop or to continue antipsychotic medication, which is exploited by some but not all 
therapists. This hypothesis is supported by the finding that - even if relapse was 
associated with stopping antipsychotic medication - at the 12-months-followup, 
patients who stopped did not have a worse outcome than those who continued. It will 
be of importance for future research to study practice guiding decisions about 
antipsychotic medication, considering the perspective that treatment without 
antipsychotics appears possible in the early phase of schizophrenia. Finally, 
evidence-based guidelines should be developed, indicating when it might be 
adequate to reduce or stop antipsychotic medication.  
 
Stopping antipsychotic medication was associated with better subjective quality of 
life. This can be explained in various ways: Some patients may have experienced 
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remission and good quality of life, and therefore decided to stop medication because 
they felt they were not in need of it anymore. The close association of relapse to 
treatment discontinuation could also indicate the possibility of high quality of life 
being a result of low illness insight (quality of life was assessed by an interview and 
mirrors the subjective experiences of patients). Clearly, neither interpretation can be 
substantiated by this study. Interestingly, relapse was associated with stopping 
antipsychotic medication in study 1, but at the 12-month-followup the patients who 
had stopped antipsychotic medication did not relapse more often (study 2). In the 
Cox-regression used in study 1, relapse was entered as a time-variant predictor, 
which analyzes mean relapse status closest to the moment of antipsychotic 
discontinuation. This indicates that circumstances in temporal proximity to stopping 
medication around the moment of discontinuing need to be seen differently from 
those evaluated over a longer time span (in our case, the full one year observational 
period).  
 
Successful discontinuation  
Despite the small number of patients who stopped antipsychotic medication 
altogether, it was possible to identify predictors of successful discontinuation. But 
results have to be interpreted with caution due to low sample size. If patients with a 
very good outcome – operationalized as having had no relapse during the study and 
showing symptomatic remission at 12-months follow-up – were considered, 
prognosis of therapists and the baseline social integration of patients were quite good 
criteria for identifying patients who will do well without antipsychotic medication. Both 
variables have previously been identified as predictors of successful discontinuation 
by other groups: Bola et al. (32) reported that patients who discontinued medication 
had a better social functioning at baseline, and prognosis was determined as being 
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related to antipsychotic-free response in another study by the same group (33). 
Although the definition of outcome and the measures used by us differ from those 
two studies, the parallels regarding predictors are intriguing. 
When a wider definition of successful discontinuation was used, namely having no 
clinical relapse during the study interval, the predictors of successful discontinuation 
were quite similar to the predictors of discontinuation (region and cardiac health), 
extended by higher baseline depression scores. The latter deserve some discussion: 
One cannot infer that first-episode patients with high initial depression scores are not 
as severely ill as patients with lower scores, as they did not have lower scores on the 
CGI. Neither were the differences in initial depression severity explained by 
diagnosis: The two diagnoses sometimes associated with better prognostic features, 
schizophreniform disorder and schizoaffective disorder, were not more common in 
the group of successful discontinuers. An earlier report from the same dataset 
describes higher initial depression scores to be associated with a better quality of life 
at follow up (34). High initial depression seems to be a positive prognostic factor, at 
least in the patient population studied in the EUFEST. This is in line with very early 
findings, which have suggested affective features to be a positive outcome predictor 
in schizophrenia (35) an issue which is still debated in the field. 
Predictors of successful discontinuation differed with the outcome definition used. A 
favourable outcome in a more stringent definition, seemed to be easier to predict for 
therapists than the mere risk for relapse.  
 
Implications 
With all due condition two main implications can be entertained based on the results 
of this study: Firstly, it is an important task for future studies to identify the processes 
involved in the decision of therapists whether to encourage a patient to continue or 
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discontinue antipsychotic medication; this would help to develop more differentiated 
guidelines for clinicians and a better information base for patients. Secondly, 
depression, prognosis and social integration seem to be important candidates for 
predicting successful drug discontinuation; their exact role and interaction have to be 
examined in future studies. 
 
Strengths and Weaknesses 
The study was designed to mirror routine clinical practice in the participating centres. 
Therefore, it was possible to identify regional differences. Results of secondary 
analyses like ours, while helping to generate hypotheses which can be prospectively 
tested in future studies, clearly cannot serve as the basis for an evidence-based 
decision process regarding the feasibility of discontinuing antipsychotic treatment in 
first episode patients.  
 Another limitation pertains to the length of follow-up. One year is definitely not long 
enough to judge the outcome of first episode psychosis. Earlier studies with longer 
observation periods have shown an ongoing progressive relapse risk beyond one 
year. It is not unlikely that a number of the “successful discontinuers” in our study 
may have experienced a relapse later on. Therefore our findings could be 
overoptimistic with regard to relapse free antipsychotic discontinuation. On the other 
hand, we may have underestimated proportions of remitted patients in EUFEST. As a 
six-month duration of symptomatic remission is part of the stricter remission criteria 
(23), patients who for instance have reached the symptomatic criteria 9 months into 
the trial could have, by definition, never met full criteria in our one year study. 
Lastly, as discussed in the primary paper (21), this was an open clinical trial with all 
the potential observation and reporting biases. Especially it could not be determined 
whether patients or therapists decided to discontinue or whether this was a joint 
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decision. On the other hand, the pragmatic study design reflecting every day clinical 
practice and the large overall sample size can be considered strengths of this clinical 
trial. 
 
Conclusions 
In a secondary analysis of the EUFEST, we have identified a significant number of 
patients who discontinued antipsychotic medication and had a good outcome 
nevertheless. Good premorbid social functioning, high depression scores at baseline 
and a clinician’s subjective evaluation of prognosis were found to predict favorable 
outcome. Results of our study should help to design future studies in which patients, 
who may be able to successfully discontinue medication after a first episode of 
psychosis, can be prospectively identified. This would add to the evidence base of 
the long term clinical management of patients suffering from a first episode of 
schizophrenia. 
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Abstract 
 
Background: 
This study aimed to identify the course of unmet needs by patients with a first 
episode of schizophrenia and to determine associated variables. 
 
Methods: 
We investigated baseline assessments in the EUFEST trial as well as follow-up 
interviews at 6 and 12 months. Latent class growth analysis was used to identify 
patient groups based on individual differences in the development of unmet needs. 
Multinomial logistic regression determined the predictors of group membership. 
 
Results: 
Four classes were identified. Three differed in their baseline levels of unmet needs 
while the fourth had a marked decrease in such needs. Main predictors of class 
membership were prognosis and depression at baseline, and the quality of life and 
psychosocial intervention at follow-up. Depression at follow up did not vary among 
classes. 
 
Conclusions: 
We identified subtypes of patients with different courses of unmet needs. Prognosis 
of clinical improvement was a better predictor for the decline in unmet needs than 
was psychopathology. Needs concerning social relationships were particularly 
persistent in subtypes who remained high in their unmet needs and who lacked 
additional psychosocial treatment. 
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Introduction 
 
Despite continuing efforts within the framework of early intervention programs to 
identify persons at risk, the initial contact with mental health services often coincides 
with a first episode of schizophrenia (Klosterkotter et al., 2005, Lester et al., 2009, 
McGorry et al., 1996, Ruhrmann et al., 2010). Early treatment reduces the potential 
for an unfavourable course that comprises persistent symptoms, (re-)hospitalisations, 
and deficits in social and vocational functioning (Addington et al., 2007, Barnes et al., 
2008, de Koning et al., 2009, Farooq et al., 2009, McGorry et al., 2010, Perkins et al., 
2005). First-episode patients benefit from a treatment approach that decreases 
psychopathological symptoms but also focuses on psychosocial functioning (Penn et 
al., 2005). In many cases, such functioning has already deteriorated before the 
exacerbation of the first psychosis; in young people, psychosocial development is 
impaired by the illness and those persons remain at a low level of functioning (Hafner 
et al., 1999). Most of the negative changes in social disability attributed to 
schizophrenia occur in the first two to five years of illness (an der Heiden and Hafner, 
2000). Thus, stopping this process is a core component of successful treatment (an 
der Heiden and Hafner, 2000). One way to develop better treatment strategies is to 
monitor changes in treatment needs over time and to identify the conditions under 
which they arise. 
 
Assessing treatment needs is an established element of clinical practice and service 
evaluation. In this context, needs are defined as the potential to benefit from (mental) 
health care (Wiersma, 2006), i.e., reversing a deficit via treatment. A more realistic 
definition states that needs are the prerequisite for maintaining or restoring an 
acceptable level of social independence and quality of life (McCrone et al., 2001). 
	  	   5	  
The concept of needs has been criticised because it pre-supposes an effective, but 
general, treatment that works for every patient with a given diagnosis, and for 
confounding the identification of a need with its potential solution (Priebe et al., 
1999a). Nevertheless, the widespread use of needs-assessment in research and 
practice calls for critical appraisal. 
 
Several interviews for assessing needs for care have been developed. The most 
commonly applied are the Needs for Care Assessment (NCA) (Brewin et al., 1987) 
and the Camberwell Assessment of Need (CAN) (Phelan et al., 1995), developed in 
the 1990s. The NCA includes an elaborate evaluation of psychopathology and 
psychosocial status. Because the NCA - and its revised form, the CNS (Marshall et 
al., 1995) - is more extensive than the CAN, usually the latter is used in larger studies 
(Kilian et al., 2001). 
 
The CAN inquires about 22 potentially problematic areas of living, and differentiates 
among 1) ‘met needs’ (patient has a specific need and this need is met by treatment), 
2) ‘unmet needs’ (specific needs that are not met by treatment), and 3) ‘no needs’ 
(patient does not have a need in this area of living). Several attempts have been 
made to establish groupings of the CAN items. Results from studies using data 
reduction techniques have been inconsistent (Korkeila et al., 2005, Wennstrom et al., 
2004), and none of the factor solutions has become widely accepted or replicated. 
Here, we propose an alternative approach in which several classes of patients are 
identified who show different trajectories of needs over time. 
  
Most research using the CAN considers only patients with a chronic or well-
established illness. We believe that ours is the first study to adopt that approach in 
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determining needs within first-episode schizophrenia. Treatment of acute episodes 
can be divided into three phases. The acute phase (weeks or a few months) is 
followed by a post-acute stabilisation phase (3 to 6 months), and then by a stable 
phase of (partial) remission (months to years) (DGPPN, 2006). All of these phases 
should be examined when evaluating the progression of needs in first-episode 
patients over time. 
 
Aims of the study 
Three questions are addressed by the present study:  
1) What is the course of needs over a 12-month period in first-episode patients 
compared with chronic schizophrenia patients? 
2) Can we identify clusters of patients with different trajectories of unmet needs? 
3) If so, what are the variables associated with those trajectories? 
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Methods 
 
Database 
Our study utilized data from the European First Episode Schizophrenia Trial 
(EUFEST) (Fleischhacker et al., 2005, Kahn et al., 2008). There, four second-
generation antipsychotics (amisulpride, 200 to 800 mg; olanzapine, 5 to 20 mg; 
quetiapine, 200 to 750 mg; and ziprasidone, 40 to 160 mg) were compared against 
each other and against treatment with a low dose of haloperidol (1 to 4 mg) (Kahn et 
al., 2008). The main outcome measure was one-year medication retention rates, i.e., 
the proportion of patients who continued with the same medicament and the initial 
dosage. In addition, a battery of outcome and diagnostic measures was assessed at 
defined time points for all patients who did not withdraw informed consent or drop out 
for other reasons. The present study investigated a selection of those measures. 
 
Sample 
Fifty mental health centres in 13 European countries and Israel were selected for 
participation. Altogether, 1047 patients were screened for eligibility between 
December 2002 and January 2006. Inclusion criteria were ages 18 to 40 years; a 
DSM-IV diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective 
disorder; onset of positive symptoms dating back two years at most; use of 
antipsychotic drugs for at most two weeks in the previous year or for at most six 
weeks at any time; and no known intolerance or contraindication for one of the study 
drugs. Diagnoses were confirmed by the International Neuropsychiatric Interview 
(MINI plus) (Sheehan et al., 1998). In all, 498 patients gave informed consent and 
were randomly assigned to five treatment groups. The study protocol was evaluated 
by local ethics committees or review boards according to country-specific laws. 
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Attrition rate 
Attrition was not similar to loss of retention of the study drug, because patients were 
followed-up beyond loss of retention. Of the 498 patients initially included, 342 
(68.7%) completed the assessments scheduled by the study according to protocol. 
Of the 156 withdrawals (31.3% of the baseline total sample), investigators withdrew 
six, while another four did not meet the inclusion criteria. The remaining 146 patients 
decided by themselves not to continue the study by withdrawal of consent or no-
show. Figure 1 presents an adapted flow chart for the sample used in our analyses 
(blue boxes). More details about the entire trial are included within the main EUFEST 
paper (Kahn et al., 2008). 
 
Figure	  1:	  Simplified	  flow	  chart	  to	  illustrate	  the	  sample	  used	  here.	  Blue	  colouring	  indicates	  
342	  patients	  who	  completed	  the	  study	  according	  to	  our	  protocol	  -­	  but	  independently	  of	  the	  
trial	  randomisation	  -­	  and	  thus	  were	  included	  in	  the	  present	  analyses. 
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Measures 
Met and unmet needs were evaluated per the Camberwell Assessment of Need 
(Phelan et al., 1995). The CAN assesses ratings by patients as well as by therapists, 
caseworkers, or research assistants. Because scores can differ substantially 
between patients and professionals, it is important to consider whose perspective is 
reported when needs are discussed (Hansson et al., 2001, Issakidis and Teesson, 
1999, Lasalvia et al., 2000, Macpherson et al., 2003, Priebe et al., 1999a, Slade et 
al., 1998, Slade et al., 1996, Wennstrom and Wiesel, 2006, Wiersma, 2006). Validity 
and reliability were previously established in several studies and deemed acceptable 
(Phelan et al., 1995). In the original paper, inter-rater reliability was r=0.99 (patients) 
and r=0.98 (staff), test-retest reliability between r=0.78 (patients) and r=0.71 (staff) 
(Phelan et al., 1995). However, test–retest reliability was not adequate for some 
single items (Kilian et al., 2001), but this could be due to skewed distributions of the 
respective items (Phelan et al., 1995). 
 
We also used the PANSS (Positive And Negative Syndrome Scale) (Kay et al., 
1987), the MANSA (Manchester Short Assessment of Quality of Life) (Priebe et al., 
1999b), the CDSS (Calgary Depression Scale for Schizophrenia) (Addington et al., 
1993), and the GAF (Global Assessment of Functioning) (Jones et al., 1995). In 
addition, the Hayward scale assessed compliance (a one-item seven-point rating 
scale, with higher scores suggesting better adherence) (Kemp et al., 1998), while 
prognosis was evaluated along a six-point scale that ranged from 1 = best to 6 = bad. 
 
The PANSS measures positive and negative symptoms and the general 
psychopathology of schizophrenia. Consisting of 30 items, it is scored by a trained 
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rater during a structured interview of 30 to 40 minutes. Leucht et al. (2005) have 
proposed that a percent reduction of 50% - respectively of 25% in treatment 
refractory patients - indicates treatment success. We use the 50% criteria even if the 
exact level of symptom reduction indicating response has been debated (e.g. Kinon 
et al., 2008), because this was just used to describe the sample. The percent 
reduction was calculated after subtracting 30 (the minimal score) from the PANSS 
sum score. The CDSS is a nine-item scale that measures, with good reliability, the 
level of depression in schizophrenia (Addington et al., 1992). A cut-off of seven 
points refers to a specificity of 82% and a sensitivity of 85% for detecting major 
depressive episodes (Addington et al., 1993). 
 
The 14 participating countries were clustered into two regions: West European (The 
Netherlands, Belgium, France, Switzerland, Austria, Germany, Sweden, Spain, and 
Italy) and East and Central European (Bulgaria, Poland, Romania, and Czech 
Republic). Because only a few patients were from Israel, that country was added to 
the West-European category to control for cell sizes and confidence intervals in the 
analyses. 
 
Socio-demographic variables were assessed at the beginning of the study (baseline, 
0 months). At each assessment, relapse and psychosocial interventions were 
described. Episodes of psychosocial treatment were recorded with beginning and 
ending dates. Compliance with medication was measured at 1, 6, and 12 months. All 
other measures were assessed at least at baseline, 6, and 12 months1. Observer-
rated measures were assessed by site coordinators or co-investigators, e.g., 
psychiatrists (including trainees), research nurses, or psychologists. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  CAN:	  0,	  6,	  12	  months;	  PANSS:	  0,	  1,	  3,	  6,	  9,	  12	  months;	  MANSA:	  0,	  3,	  12	  months;	  CDSS:	  0,	  1,	  3,	  6,	  12	  months;	  GAF:	  0,	  1,	  2,	  3,	  6,	  9,	  12	  months;	  Hayward	  Compliance:	  1,	  6,	  12	  months.	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Statistical analyses 
The analyses are preceded by a comparison between the baseline sample 
characteristics of completers and the baseline characteristics of the complete 
sample. We used SPSS (PASW Statistics 18.0 for Windows) to calculate t-tests for 
continuous variables (or the non-parametric equivalent Mann-­‐Whitney test for 
variables with non-normal distributions) and Chi-square statistics for categorical 
variables. 
 
Because we were interested in individual trajectories of unmet needs over three time 
points, we developed a latent class growth model via Latent Gold 4.5. This modelling 
technique identifies different types of patients by estimating continuous latent 
variables for individual intercepts and slopes, as well as a categorical latent variable 
that represents groups with similar trajectories (Nagin, 1999). The analysis was 
based on the sum score of unmet needs. Our aim was to identify groups of patients 
as determined by maximally distinct trajectories of needs between groups and 
minimally distinct individual trajectories within groups. The number of groups was 
obtained statistically by comparing the model-fit indices of models with successive 
numbers of clusters. Because data were sparse, model significance (P-value 
associated) with the L2 fit statistic was assessed using the bootstrap option within 
Latent Gold 4.5 rather than with standard chi-square values. Model fit was based 
upon the Bayesian Information Criterion (BIC). To decide on the final model, 
statistical fit indices were supplemented by the criteria of suitability for answering the 
research question, parsimony, theoretical justification, and interpretability (Muthén 
and Muthén, 2000). The sum of unmet needs was defined as a count variable. 
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Finally, we determined the predictors of membership for latent clusters of unmet-
needs trajectories and the outcomes of clusters. Although Latent Gold 4.5 allows one 
to include predictors directly, that option is restricted to categorical variables. 
Because the measures used in this EUFEST study were count, ordered-categorical, 
or continuous, we preferred a multinomial logistic regression with cluster membership 
as the dependent variable. In the bivariate multinomial regressions, associated 
variables were selected on the basis of their significance (P<0.1 to consider weak 
effects also). Positive and negative symptoms, insight (one item from the PANSS), 
gender, region, and age were included by default. In the outcome model, follow-up 
values for the same longitudinal variables were used, and information was added for 
the number of relapses and psychosocial intervention (duration of one month or 
longer). In the combined multinomial regression model, variables with significant 
Likelihood Quotient Test (P<0.05) were considered main influences. Those that 
discerned only one group from another due to a significant odds ratio, but without any 
significant Likelihood Quotient Test, were also discussed. Multinomial regression was 
calculated with SPSS. 
 
Differences in single needs that arose between assessment periods were not 
subjected to statistical testing because of limited cell sizes. 
 
 
Results 
 
Sample characteristics 
The sample of study completers was used in our analyses. The mean age was 26.1 
years at baseline, and more men (56.4%) participated than women (Table 1). Greater 
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than half of the sample (59.6%) was from Central and East European countries. 
Paranoid schizophrenia (45.3%) and schizophreniform disorder (40.1%) were the 
most prevalent diagnostic categories.  
 
Table	  1:	  Descriptive	  statistics	  of	  selected	  variables	  at	  baseline	  (total	  sample,	  N=498)	  and	  
sample	  of	  completers	  (N=342).	  	  
 Baseline	  
total	  	  
 
	   Baseline	  
completers	   
	   Dropouts	   	   Difference:	  
dropouts	  –	  
completers2 
 mean	  ±SD	  /	  
percent	  
N	   mean	  ±SD	  /	  
percent	  
N	   mean	  ±SD	  /	  
percent	  
N	   P	  
Age	  at	  baseline	  (yr) 25.98	  ±5.55 (498)	   26.05	  ±5.64 (342)	   25.83	  ±5.38	   (156)	   0.618	  
Gender	  (women) 40.2% (200)	   43.6% (149)	   32.7%	   (51)	   0.024 
Cultural	  region    	   	   	   0.000 
	  	  	  West	  Europe 34.9% (174)	   28.9% (99) 48.1%	   (75)	   -­	  
	  	  	  East/Central	  Europe 51.4% (256)	   59.6% (204)	   33.3%	   (52)	   -­	  
	  	  	  Israel 13.7% (68)	   11.4% (39)	   18.6%	   (29)	   -­	  
Occupation	  at	  baseline	  (yes) 46.6% (231)	   46.5% (159)	   46.8%	   (72)	   1.000	  
Antipsychotic	  naïve	  at	  baseline	   32.5% (162)	   30.7% (105)	   36.5%	   (57)	   0.216	  
DSM-­III-­R	  diagnosis    	   	   	   0.603	  
	  	  	  Disorganized,	  catatonic,	  
undifferentiated 
8.4% (42)	   7.3% (25)	   10.9%	   (17)	   -­	  
	  	  	  Paranoid 44.8% (223)	   45.3% (155)	   43.6%	   (68)	   -­	  
	  	  	  Schizophreniform 39.8% (198)	   40.1% (137)	   39.1%	   (61)	   -­	  
	  	  	  Schizoaffective 7.0% (35)	   7.3% (25)	   6.4%	   (10)	   -­	  
Met	  needs	  patient,	  sum 2.59	  ±2.57 (470)	   2.78	  ±2.73 (333)	   2.15	  ±2.06	   (137)	   0.007/0.034	  
Unmet	  needs	  patient,	  sum 2.04	  ±2.07 (470)	   2.19	  ±2.14 (333)	   1.66	  ±1.82	   (137)	   0.012/0.013	  
MANSA	   4.04	  ±0.92	   (483)	   3.98	  ±0.90	   (339)	   4.19	  ±0.96	   (144)	   0.023/0.022	  
GAF	   40.03	  
±13.51	  
(490)	   40.72	  ±13.50	   (341)	   38.46	  ±13.44	   (149)	   0.087/0.107	  
PANSS	  total	  score 88.53	  
±20.63 
(487)	   89.06	  ±20.69 (340)	   87.29	  ±20.49	   (147)	   0.386/0.371	  
PANSS	  positive	  symptoms	   23.13	  ±6.19	   (489)	   23.36	  ±6.17	   (340)	   22.59	  ±6.23	   (149)	   0.205/0.138	  
PANSS	  negative	  symptoms	   21.23	  ±7.62	   (489)	   21.14	  ±7.73	   (341)	   21.42	  ±7.41	   (148)	   0.714/0.793	  
CDSS,	  sum	  score 5.07	  ±4.87 (488)	   5.27	  ±4.88 (341)	   4.62	  ±4.84	   (147)	   0.176/0.140	  
Prognosis	  by	  investigators	   3.19	  ±1.19	   (495)	   3.10	  ±1.18	   (342)	   3.39	  ±1.19	   (153)	   0.014/0.014	  
Compliance	  (at	  1	  month) 5.57	  ±1.20 (453)	   5.66	  ±1.16 (337)	   5.30	  ±1.29	   (116)	   0.006/0.006	  
 
Significant, but not large dropout effects (differences in baseline scores between 
completers and dropouts) were found for the following variables: gender (more male 
dropouts), region (fewer dropouts in East- and Central European countries), 
treatment compliance (more adherent patients completed the study), and prognosis 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Significance	  of	  differences	  between	  baseline	  completers	  and	  dropouts	  was	  calculated	  for	  each	  continuous/count/ordinal	  variable	  with	  t-­‐tests	  (first	  P-­‐value),	  to	  control	  for	  non-­‐normal	  distributions	  with	  the	  Mann-­‐Whitney	  Test	  (second	  P-­‐value),	  and	  with	  chi-­‐square	  tests	  for	  nominal	  variables.	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(completers had a better prognosis). Finally, completers had more met and unmet 
needs at baseline than did dropouts. 
 
From baseline to 12 months of follow-up, 78.7% (263 of 334 completers) reached a 
50% reduction in their PANSS total scores. At baseline, 36.1% (123 of 341) had a 
diagnosis of major depression according to the CDSS score; at 12 months, this was 
only 3.5% (12 of 340). Most subjects were part of inpatient treatment settings at the 
beginning of the study (89.8%; 307 of 342) versus only 4.7% (16 of 340) at the 12-
month follow-up. About 32.5% of the patients (111 of 342) had received some 
psychosocial treatment during at least one month. 
 
Figure 2 depicts the course of patient-rated met and unmet needs, measured by the 
CAN. Both clearly decreased from baseline to six months. While the number of met 
needs continued to decline in the second half of the study, the amount of unmet 
needs tended to remain stable over that period. Compared with baseline findings, at 
12 months 65.0% (N=208) patients had fewer unmet needs, 27.5% had an equal 
number, and 7.5% (24) had more. At baseline, met needs were slightly more frequent 
than unmet needs (ratio met/unmet = 1.41), but after 6 and 12 months, at least two 
out of three needs were met (ratio met/unmet = 2.41 and 1.96, respectively) (Figure 
2). 
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Figure	  2:	  Means	  for	  number	  of	  met	  needs,	  unmet	  needs,	  and	  ratios	  for	  met	  needs	  /	  unmet	  
needs	  according	  to	  patient	  ratings	  from	  baseline	  (T1)	  to	  6	  months	  (T7)	  and	  12	  months	  
(T9)	  in	  the	  EUFEST	  trial.	  All	  patients	  providing	  CAN	  ratings	  at	  the	  respective	  assessments	  
were	  included.3	  
 
Differences in the course of unmet needs between patient classes  
A four-class model describing the course of unmet needs best fitted the data (Figure 
3). This solution fulfilled other criteria of model usability, being practical and easy to 
explain (Muthén and Muthén, 2000). Class 1 (autonomous group) had few unmet 
needs and a diminishing trend between baseline and six months. A second started 
with a mean of 2.5 unmet needs, then declined sharply to 1.25 from baseline to six 
months and slowly to 1.15 afterward (ordinary group, Class 2). Our uncomplicated 
group (Class 3) started with 4.5 unmet needs, then markedly decreased to nearly 
zero unmet needs in the first six months before showing no other change. Finally, 
Class 4 (complicated group) began with nearly 5.0 unmet needs at baseline, which 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  Ratios:	  If	  a	  person	  indicated	  no	  unmet	  needs,	  the	  respective	  case	  was	  set	  to	  the	  „system	  missing“	  value.	  Therefore,	  the	  sample	  from	  ratios	  is	  much	  smaller	  than	  the	  sample	  used	  for	  sum	  scores.	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distinctly dropped to 3.75 at six months before increasing to 4.0 unmet needs by 
Month 12.  
 
 
Figure	  3:	  Four-­class	  model	  of	  sum	  of	  unmet-­need	  patient	  ratings	  (Total	  N=338).	  Lines	  
represent	  mean	  number	  of	  unmet	  needs	  in	  each	  class.4	  T1=Baseline,	  T7=6	  months,	  T9=12	  
months.	  
 
When the ratio of met to unmet needs was considered, change in the first six months 
was greatest in the uncomplicated group, i.e., from a ratio of 0.74 at baseline the 
ratio increased to 4 met needs per 1 unmet need (N=2). In contrast, ratios for the 
complicated class remained relatively stable over the three time points (0.80, 1.51, 
1.37).  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  The	  four-­‐class	  model	  was	  selected	  according	  to	  the	  BIC	  criterion.	  Class	  sizes	  were	  N(c1)=170,	  N(c2)=77,	  N(c3)=56,	  N(c4)=35.	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Predictors and outcomes of needs course 
Covariates of the course of unmet needs that were significant at P<0.1 in bivariate 
analysis were combined in one multinomial regression model. Positive and negative 
symptoms as well as the item “insight” from the PANSS were included by default. 
Table 2 shows our results from the multinomial regression analysis of baseline 
variables. The autonomous group was chosen as the reference class. From our 
model, the significant predictors at baseline were depression (means: Class 1 = 4.17, 
Class 2 = 5.25, Class 3 = 8.00, Class 4 = 6.51), prognosis (Class 1 = 2.92, Class 2 = 
3.43, Class 3 = 2.93, Class 4 = 3.60), age (Class 1 = 25.78, Class 2 = 27.26, Class 3 
= 25.06, Class 4 = 26.16), region (West Europe and Israel, Class 1 = 33.5%, Class 2 
= 53.2%, Class 3 = 41.1%, Class 4 = 37.1%) and being antipsychotic naïve (Class 1 
= 32.9%, Class 2 = 26.0%, Class 3 = 39.3%, Class 4 = 14.3%) according to the 
Likelihood Quotient Test (P>0.05). Patients in the ordinary group had less favourable 
prognoses than those in the reference group. Persons with an uncomplicated course 
were distinguished from the autonomous group only by higher depression scores and 
lower quality of life at baseline. Patients with a complicated-needs course were more 
often male, had higher baseline depression scores, a less favourable prognosis, and 
lower compliance. Moreover, they included more patients who already had used 
antipsychotic medication before the study began. Prognosis at baseline indirectly 
separated the complicated from the uncomplicated group. 
 
Values for variables used in the baseline model – age, region, and gender – were 
included in the follow-up model (Table 2), as were the number of relapses and 
psychosocial intervention (duration of at least one month). Psychosocial interventions 
(Class 1 = 35.3%, Class 2 = 42.9%, Class 3 = 25.0%, Class 4 = 11.4%) and quality 
of life (Class 1 = 5.06, Class 2 = 4.66, Class 3 = 4.82, Class 4 = 4.16) were 
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significant covariates in the model (Likelihood Quotient Test P>0.05). None of the 
follow-up variables differentiated between the autonomous (reference) and the 
ordinary group. The uncomplicated group had lower functioning scores at follow-up 
compared with the reference group. The complicated group had fewer psychosocial 
interventions, lower quality of life, more positive symptoms, fewer negative 
symptoms, and better compliance than did the autonomous group (Table 2).  
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Table	  2:	  Baseline	  and	  follow-­up	  covariates	  of	  unmet	  needs	  by	  different	  trajectory	  classes	  
(total	  N	  =	  331	  at	  baseline	  and	  N	  =	  327	  at	  follow-­up).	  Reference	  class:	  Class	  1	  “autonomous”	  
(N=167).5	  6	  
	   Class	  2	  “ordinary”	   Class	  3	  “uncomplicated”	   Class	  4	  “complicated”	  
	   OR	   (lower-­upper	  
95%	  CI)	  
OR	   (lower-­upper	  95%	  
CI)	  
OR	   (lower-­upper	  
95%	  CI)	  
Baseline	   	   	   	   	   	   	  
GAF	  functioning	   0.99	   (0.97-­1.01)	   0.98	   (0.95-­1.00)	   0.97	   (0.93-­1.01)	  
CDSS	  Depression	  score	   1.04	   (0.97-­1.11)	   1.14	   (1.06-­1.23)	   1.13	   (1.02-­1.25)	  
MANSA	  Quality	  of	  Life	   0.70	   (0.49-­1.01)	   0.63	   (0.41-­0.97)	   0.60	   (0.36-­1.02)	  
PANSS	  positive	   1.00	   (0.94-­1.06)	   1.04	   (0.97-­1.11)	   0.95	   (0.86-­1.04)	  
PANSS	  negative	   0.99	   (0.95-­1.03)	   0.96	   (0.92-­1.01)	   0.95	   (0.89-­1.01)	  
PANSS	  insight	   1.02	   (0.80-­1.31)	   0.86	   (0.64-­1.15)	   0.81	   (0.55-­1.18)	  
Prognosisa	   1.33	   (1.03-­1.73)	   1.07	   (0.78-­1.47)	   1.74	   (1.16-­2.60)	  
Compliance	  1	  month	   0.92	   (0.69-­1.22)	   0.99	   (0.70-­1.39)	   0.62	   (0.42-­0.92)	  
Age	   1.05	   (1.00-­1.10)	   0.96	   (0.90-­1.03)	   0.99	   (0.91-­1.07)	  
Men	  (ref)b	   .	   	   .	   	   .	   	  
	  	  Women	   0.55	   (0.30-­0.95)	   0.69	   (0.35-­1.38)	   0.35	   (0.14-­0.89)	  
East/Central	  Europe	  (ref)	   .	   	   .	   	   .	   	  
	  	  West	  Europe	   1.85	   (0.98-­3.48)	   1.12	   (0.54-­2.33)	   0.37	   (0.13-­1.09)	  
Occupation	  yes	  (ref)	   .	   	   .	   	   .	   	  
	  	  Occupation	  no	   1.41	   (0.76-­2.63)	   1.07	   (0.53-­2.16)	   2.37	   (0.86-­6.55)	  
Not	  naïve	  (ref)	   .	   	   .	   	   .	   	  
	  	  naïve	   0.60	   (0.31-­1.16)	   1.09	   (0.54-­2.21)	   0.20	   (0.06-­0.68)	  
Follow-­up	   	   	   	   	   	   	  
GAF	  functioning	   0.98	   (0.95-­1.01)	   0.97	   (0.93-­1.00)	   0.96	   (0.92-­1.00)	  
CDSS	  Depression	  score	   1.03	   (0.88-­1.20)	   0.97	   (0.80-­1.17)	   1.15	   (0.94-­1.41)	  
MANSA	  Quality	  of	  Life	   0.67	   (0.42-­1.07)	   0.68	   (0.40-­1.13)	   0.30	   (0.15-­0.60)	  
PANSS	  positive	  sym.	   1.10	   (0.99-­1.22)	   1.09	   (0.97-­1.23)	   1.15	   (1.01-­1.31)	  
PANSS	  negative	   0.95	   (0.89-­1.02)	   0.93	   (0.87-­1.01)	   0.89	   (0.80-­0.98)	  
PANSS	  insight	   1.02	   (0.73-­1.41)	   0.76	   (0.51-­1.13)	   0.91	   (0.56-­1.49)	  
Compliance	   1.22	   (0.97-­1.53)	   1.11	   (0.86-­1.42)	   1.49	   (1.05-­2.13)	  
Psych.	  interv.	  yes	  (ref)	   	   	   	   	   	   	  
	  	  no	   1.05	   (0.53-­2.31)	   1.98	   (0.89-­4.42)	   5.82	   (1.51-­22.50)	  
Number	  relapses	   1.34	   (0.72-­2.49)	   0.98	   (0.46-­2.09)	   1.31	   (0.58-­2.98)	  
Age	   1.04	   (0.99-­1.10)	   0.97	   (0.91-­1.04)	   0.98	   (0.90-­1.06)	  
Men	  (ref)*	   .	   	   .	   	   .	   	  
	  	  Women	   0.60	   (0.32-­1.12)	   0.84	   (0.43-­1.65)	   0.38	   (0.14-­1.00)	  
East/Central	  Europe	  (ref)	   .	   	   .	   	   .	   	  
	  	  West	  Europe	   1.84	   (0.53-­2.06)	   1.39	   (0.62-­3.07)	   1.02	   (0.33-­3.09)	  
a	   Prognosis	  is	  inversely	  scored:	  higher	  scores	  mean	  a	  more	  unfavourable	  prognosis	  
b	   Reference	  Category.	  This	  parameter	  is	  set	  to	  zero	  because	  it	  is	  redundant.	  
 
Specific unmet needs 
In all four classes, daytime activities, psychotic symptoms, psychological distress, 
and social integration were most often rated as unmet needs (Figure 4a). In areas of 
life where unmet needs were prevalent at baseline, some still remained unmet after 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  According	  to	  the	  Likelihood	  Quotient	  Test,	  the	  omitting	  of	  region,	  CDSS,	  being	  antipsychotic	  naïve	  at	  baseline,	  and	  prognosis	  led	  to	  significantly	  different	  models	  (P<0.05).	  Overall	  model	  fit:	  Chi-­‐square	  118.066,	  Df	  39,	  P<0.000.	  Pseudo	  R-­‐square:	  Cox	  &	  Snell	  0.300,	  Nagelkerke	  0.329,	  McFaden	  0.148.	  6	  According	  to	  the	  Likelihood	  Quotient	  Test,	  only	  the	  omissions	  of	  MANSA	  and	  psychosocial	  intervention	  led	  to	  significantly	  different	  models.	  Overall	  model	  fit:	  Chi-­‐square	  104.402,	  Df	  36,	  P<0.000.	  Pseudo	  R-­‐square:	  Cox	  &	  Snell	  0.273,	  Nagelkerke	  0.300,	  McFaden	  0.131.	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12 months. Met needs (Figure 4a) were more persistent, being associated with 
hardly any reduction in psychotic symptoms and social integration. Figure 4b depicts 
the change in specific unmet needs for each class. A bar corresponds to the total 
change in a particular item in the total sample (=100%). Each bar contains 
information on change in the four classes. The negative section of the bars 
represents fewer unmet needs at 12 months than at baseline while the positive 
portion corresponds to an augmentation in unmet needs. For example “intimate 
relationship”: change in class 1 = -6, change in class 2 = -1, change in class 3 = -18, 
change in class 4 = +7; total change in unmet needs = 28 (100%).  
Those needs concerning self-care, sexual expression, education, and transport 
became more frequent in the ordinary group whereas those related to sexual 
expression, intimate relationship, company, education, looking after home, and 
money became more frequent in the complicated group.  
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Figure	  4a:	  Distribution	  of	  needs	  in	  detail.	  Bars	  represent	  numbers	  of	  met	  (triangles)	  and	  
unmet	  (darker	  bars)	  needs	  at	  baseline	  (T1);	  crosses	  (met	  needs)	  and	  lighter	  bars	  (unmet	  
needs)	  represent	  numbers	  of	  needs	  at	  the	  12-­month	  follow-­up	  (T9).	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Figure	  4b:	  Percent	  change	  between	  baseline	  (T1)	  and	  12-­month	  follow-­up	  (T9)	  in	  single	  
unmet	  needs	  in	  the	  four	  classes.	  100%	  represents	  the	  total	  change	  in	  a	  particular	  item	  in	  
the	  total	  sample.	  The	  coloured	  bars	  represent	  how	  much	  of	  this	  change	  was	  present	  in	  each	  
of	  the	  latent	  classes.	  Positive	  values	  =	  more	  unmet	  needs,	  negative	  values	  =	  reduction	  in	  
unmet	  needs. 
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Discussion 
 
Information is scarce about the course of treatment needs for persons in the early 
stages of schizophrenia. We analyzed patient ratings of needs over a 12-month span 
in a homogenous sample of participants suffering from first-episode schizophrenia. It 
became clear that the first six months were of outmost importance to treatment 
because the largest proportion of change in needs occurred during that period.  
 
The EUFEST sample contains many relatively well-integrated patients who possibly 
will never become chronically ill. Accordingly, the degree of reduction in unmet needs 
over time has proven more pronounced in that study than in other research 
encompassing the same time span in longer established illness (Priebe et al., 2002). 
Because the EUFEST sample was homogenous for the phase of illness at baseline, 
the majority of patients made a transition from the acute phase of illness to remission 
after about six months. They then reached the stabilisation phase during the second 
half of the study. At least at baseline, all were under neuroleptic medication, which 
helped reduce symptoms and contributed to an initial decline in unmet treatment 
needs in the majority of patients. Neither the duration of medication nor first- versus 
second-generation neuroleptic medication had a significant impact on the course of 
unmet needs. However, a floor effect may have been responsible for the relatively 
stable course of unmet needs between 6 and 12 months. 
 
The overall curve of unmet needs was composed of three groups that differed mainly 
in their baseline numbers of unmet needs, plus one relatively small group that 
showed a marked decline in those needs. The largest group had few unmet needs 
throughout the study. From the beginning, patients from this group had better 
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prognoses than those who remained higher in unmet needs. They also experienced 
less depression and a better quality of life than did patient groups with more initial 
unmet needs. This group was called the “autonomous” group because they had 
fewer unmet needs, even if they did not have more psychosocial interventions. The 
“ordinary” group had slightly more unmet needs throughout the study compared with 
the autonomous group, as well as a less favourable initial prognosis. Accordingly, 
more patients in this group underwent some type of psychosocial treatment. Although 
many of their unmet needs had disappeared by Month 6, those that concerned 
education and transport, which might become more important in more stable phases 
of illness, had increased. Patients in the “uncomplicated group” had relatively 
numerous unmet needs at the beginning but then showed a very steep decline from 
baseline until the six-month assessment, even if they did not have more frequent 
psychosocial treatment than the other two groups. Strong initial depression and low 
quality of life might have been reasons for the elevated number of unmet needs at 
baseline. Patients in the “complicated group” who had rather elevated levels of unmet 
needs over the entire time span had more initial depression, as was also found with 
the uncomplicated group. However, they seemed to miss the opportunity for 
recovery, as evidenced by their greater number of positive symptoms at follow-up 
compared with other groups. The lack of psychosocial interventions might have been 
a reason for this because patients’ psychosocial needs had increased at the time of 
follow-up.  
 
Some processes that influence the course of unmet needs merit a closer look. For 
example, high depression scores at the beginning of our study coincided with a high 
degree of unmet needs. However, depression did not differ between the 
uncomplicated group with declining unmet needs and the complicated group that 
	  	   25	  
sustained a high level of such unmet needs. Because depression during the follow-
up period was no longer associated with various courses of needs, this finding 
cannot be explained by a self-rating bias of both instruments (Hansson et al., 2007). 
Findings that concern predictions of later depressive episodes based upon 
depression in the prodromal or acute states are unequivocal (an der Heiden and 
Hafner, 2000, Birchwood et al., 2000, Upthegrove et al., 2010). Our results might 
also be interpreted as evidence that depression in the acute phases does not have to 
be exactly the same as depression in later phases of schizophrenia. Patients in acute 
phases of schizophrenia probably do not entirely realize that they need help because 
of their contemporaneous delusions and grandiosity. By contrast, depression 
implicates a stronger urge to seek assistance and greater insight into their illness, 
thereby leading them to a greater recognition of those needs (Mintz et al., 2003, 
Schennach-Wolff et al., 2011). By the later phases, working alliances might develop 
and patients may learn to rate their need for treatment independently of depressive 
symptoms. However, the missing impact of insight revealed in our study discounts 
this hypothesis. 
 
Surprisingly, neither baseline positive nor negative symptoms were relevant. 
However, at follow-up, positive and negative symptoms as well as functioning 
differed among the groups. One possible conclusion is that neither psychotic 
symptoms nor depression and functioning in acute phases could predict whether 
patients would require more intensive help, especially with social needs. 
Nevertheless, at follow up there may have been larger differences among patients 
(i.e. whether they are in acute or stabilisation phase of illness), and therefore, 
stronger effects of psychopathology. A more profound examination of the topic would 
be interesting. For now, this lies beyond the scope of our paper. 
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The prognosis of clinical improvement appeared to discern the uncomplicated and 
complicated needs course in patients with initially high numbers of unmet needs. 
Thus, the prognosis was quite exact because patients remaining high in unmet needs 
also had more positive symptoms or lower functioning scores at follow-up. However, 
our data did not clearly indicate the basis upon which investigators drew their 
conclusions concerning prognosis. There, an ad-hoc scale was applied, for which 
psychometric properties have not been ascertained. Despite the correct prognosis at 
baseline, patients with a complicated needs course had less frequent psychosocial 
interventions. This could not have been explained as a failure to recognize their own 
needs because, at both baseline and follow-up, those patients had indeed expressed 
psychosocial needs. In general, the persistently high occurrence of unmet social 
needs in patients with a complicated course demonstrates the necessity to address 
social and relationship needs during both acute and post-acute phases of illness. 
Impairments in (social) functioning can also be very stable in the middle and late 
courses of schizophrenia (Hafner et al., 1999). Antipsychotic treatment alone is not 
sufficient to improve such functioning (Swartz et al., 2007). By attending to unmet 
social needs at the early stages, one can prevent the progressive loss of meaningful 
relationships. Although we could not obtain information for why those patients with 
many needs did not receive help, these results indicate the importance of studying 
the processes that lead to a clinical prognosis as well as the relationship between 
that prognosis and treatment-planning in first-episode patients. 
 
Whereas revealing more unmet needs at follow-up coincided with better compliance, 
at baseline the opposite was true. Using univariate analysis, we found similar effects 
of compliance at baseline and follow-up. Therefore, compliance was better in patients 
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with more unmet needs later on, but only with regard to other variables that were 
included in the follow-up model.  
 
Summary 
Results from this study demonstrated that, in a sample of first-episode patients, 
strong differences were found among their one-year courses of treatment needs. An 
unfavourable course of unmet needs coincided with more positive symptoms. 
Psychosocial treatment seemed to play a critical role in influencing the development 
of unmet needs. Whether investigators are able to predict those courses and whether 
psychosocial treatment really is responsible for an improved needs course must be 
confirmed by studies that utilize more elaborate assessments. This may potentially 
identify those patients at risk for more unfavourable courses, thereby prompting 
attention to reduce their unmet needs. 
 
Limitations 
One limitation to the generalizing of these results was participants’ attrition. Our 
results were valid only for patients who completed the study; it is unclear whether the 
data would have been the same if all patients had been included. We did not use 
imputation of missing values because they were not randomly distributed. Because 
unmet needs and several other variables were predictors of missingness, such 
imputation would have borne a high risk of biasing the results. 
 
A second limitation lay within the analytic strategy. Low levels of unmet needs can be 
due to generally few needs, but may also be a consequence of many needs being 
met. The approach we used did not differentiate between those conditions. 
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Other limitations were due to instruments and study design. For example, the CAN is 
not devised especially for first-episode schizophrenia. If needs exist that are 
exclusively relevant in this phase of illness, they may be missed by the CAN. Needs 
were assessed during a controlled randomized trial that was aimed, instead, at 
testing different neuroleptic medications. Other factors may have influenced the 
course of unmet needs that were not addressed in this study. 
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Abstract  
 
Background: 
The interrelation between needs for care and quality of life has been described and 
replicated by several studies. The present work aims to add to the understanding of 
longitudinal interrelations between needs for care, quality of life, and other outcome 
measures by analyzing a sample of patients at the onset of schizophrenia. 
 
Methods: 
This study relied on data from the EUFEST trial, designed to compare first- and 
second-generation antipsychotics during one year. At baseline, 498 patients have 
been included. The first (baseline) and the last assessment (12 months after 
baseline) were used for the analyses. Predictors of quality of life were determined 
using regression analyses. We tested the complex longitudinal interrelations between 
baseline and outcome measures with structural equation models. 
 
Results: 
Unmet needs were not definitively confirmed as a predictor of subsequent quality of 
life, unless unmet needs changing to no needs were separated from unmet needs 
changing to met needs. Each unmet need that changed to no need enhanced quality 
of life (mean score 1 - 7) by 0.136 scale points. 
 
Conclusions: 
This study suggests that when studying quality of life and needs for treatment, it is 
crucial to differentiate whether unmet needs disappeared or whether they were met, 
as the former has a stronger impact on quality of life.
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Introduction 
 
Addressing the needs of psychiatric patients has become an important indicator for 
assessing the quality of mental health services. It is understood that each patient has 
individual needs but that there are illness specific needs common to patient groups. 
Needs of patients could, in principle, be satisfied by providing effective treatment. 
Needs are commonly differentiated into met and unmet. Unmet needs are ongoing 
serious problems of an individual patient, whether or not help is provided whereas 
met needs are absent or moderate problems because help is provided and 
successful [23]. For example an unmet need is when someone does not know where 
to live after leaving the hospital. The need is met when this person has an interim 
solution and receives help with finding a new apartment. Met needs are further 
distinguished from no needs, as they continue to be needs despite the temporary 
relief afforded by treatment. For example, no need is when the living situation of a 
patient is satisfactory. If previously unmet needs can be satisfied, or if the number of 
unmet needs has simply declined over time, it is assumed that treatment has been 
effective [31]. Although the assessment of treatment needs is widely used, its validity 
as an outcome measure remains contested as oversimplifying the process of clinical 
decision making and individual recovery processes of patients [24]. 
 
It is assumed that a change from unmet to met needs of patients should improve 
their quality of life [31]. Enhancing quality of life is a major goal of treatment, 
especially in patients suffering from severe and chronic mental disorders. Quality of 
life encompasses, as a broad outcome measure, satisfaction with several domains of 
individual life. The domains of quality of life and the domains of needs overlap in part 
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(e.g. living situation, work and social relations) [26]. At least a weak interrelation of 
the two concepts can be anticipated.  
 
Usually, needs are assessed with structured interviews, the most common being the 
Camberwell Assessment of Need (CAN) [23], and the Needs for Care Assessment 
(NCA) [5]. Cross sectional studies [3, 9, 10, 32, 35, 39] have confirmed the 
interrelation between unmet needs and quality of life including patients with high, 
medium and low levels of functioning [3]. For met needs, the interrelation with quality 
of life was less consistent. Some studies found a negative association (the more met 
needs the lower the quality of life) [32, 39], others did not find such an association 
[10]. The assumption that more met needs would be associated with higher quality of 
life was not confirmed.  
 
However, cross-sectional studies are not sufficient to resolve questions of causal 
interrelations. Longitudinal association is one criteria of establishing causality [4]. The 
few longitudinal studies testing the interrelation of quality of life and needs yielded 
inconsistent results. Slade and colleagues found that the average level of unmet 
needs and changes in unmet needs preceded quality of life [30]. Patient-rated unmet 
needs were a stronger predictor of subsequent quality of life than social role 
functioning, psychopathology, satisfaction with services, and therapists’ ratings of 
needs [31]. Hansson & Björkman [9], on the contrary, did not find any longitudinal 
associations between needs and quality of life. 
 
The aim of the present study was to gain greater insight in the longitudinal 
interrelation between quality of life, unmet needs, symptom severity, clinical status 
and social functioning. As a met need is defined as a need that is met by treatment, it 
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has to be differentiated from a need that has disappeared during treatment. 
Therefore we were interested whether the change from unmet needs to met needs 
[31], but also to no needs is associated with improvement in quality of life. The 
secondary aim was to describe the interrelation of needs and quality of life in a 
homogenous sample of patients moving from the acute first episode to the remission 
and stabilisation phases of schizophrenia.  
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Methods 
 
Database 
The present study used the data of the European First Episode Schizophrenia Trial 
(EUFEST) [8, 15]. The EUFEST study aimed to compare second-generation 
antipsychotics with low doses of haloperidol [15]. The main outcome measure was 
one-year retention rates of medication. In addition, a battery of outcome- and 
diagnostic measures was assessed at several defined points in time. The present 
study includes psychosocial and psychopathological outcome measures assessed at 
baseline and after 12 months, as needs and quality of life were assessed 
simultaneously only twice, at the beginning and end of the study. Although the 
EUFEST trial addressed some weaknesses of previous antipsychotic drug trials (for 
critique of previous studies see [19]), other methodological aspects can be criticised: 
Among other, EUFEST was not blinded [8] and thus is supposed to favour all 
second-generation antipsychotics [19]; also the analytic strategy used in EUFEST 
has been criticised [7]. But most critiques are focused on the comparison of first- and 
second-generation antipsychotics. The present study does not analyze medication, 
therefore most of this limitations do not apply. Limitations relevant to this study are 
discussed in the limitations section. 
 
Sample 
Fifty centres from 13 European countries and Israel were selected for participation. 
Altogether, 1047 patients were screened for eligibility between the December 2002 
and January 2006. Inclusion criteria were age between 18 and 40 years, and a DSM-
IV diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder, 
onset of positive symptoms dating back at most two years; use of antipsychotic drugs 
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for at most two weeks in the previous year or for at most 6 weeks at any time; and no 
known intolerance or contraindication for one of the study drugs. Diagnoses were 
confirmed by the International Neuropsychiatric Interview (MINI plus [29]). 498 
patients gave informed consent and were randomly allocated to five treatment 
groups. The study protocol was subjected to the local ethic committees or review 
boards according to the country specific laws. 
 
Attrition rate 
Of the 498 patients initially included, 342 (68.7%) completed according to the 
protocol. Of the 156 (31.3%) withdrawals, investigators withdrew 6, and 4 did not 
meet the inclusion criteria. The remaining 146 patients have decided by themselves 
to quit the study. 
 
Measures 
Met and unmet needs were assessed using the Camberwell Assessment of Needs 
(CAN) [23]. The CAN is a 22-item measure encompassing several domains of life 
that are potentially problematic for people suffering from mental illness. Domains of 
life are for example: “psychotic symptoms”, “accommodation”, “day time activities”, 
“intimate relationship”, but also “transport” or “money”. For each domain, the 
presence of needs and the coverage of needs by treatment are collected. Validity 
and reliability of the CAN are considered to be acceptable [23]. The construction of 
adequate summary indices is controversial [21, 36-38], but most studies rely on sum 
scores of met and unmet needs. The CAN allows for ratings by patients and ratings 
by professionals (e.g. therapists, caseworkers or research assistants). The Kappa 
coefficients for the agreement between ratings of professionals and patients are 
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between 0.18 – 0.53 [11, 12, 18, 33, 34, 38]. In the present study, sum scores of 
patient-rated met and unmet needs are used. 
 
The Manchester Short Assessment of Quality of Life (MANSA) [25] is a widely used 
measure of quality of life encompassing 16 items, four questions about objective and 
twelve questions assessing subjective quality of life by asking patients about their 
satisfaction with several domains of life. Answers for subjective quality of life are on a 
7 point scale ranging from 1=”could not be worse” to 7=”could not be better”. We 
used the mean of the 12 patient-rated subjective questions to calculate a quality of 
life score. 
 
Other measures used in the present study were the PANSS (Positive And Negative 
Syndrome Scale [16]), the CDSS (Calgary Depression Scale for Schizophrenia [1]) 
measuring the level of depression in schizophrenia and the GAF (Global Assessment 
of Functioning [14]). The Hayward Scale [17] was used to assess compliance (one-
item 7-points rating scale with higher scores suggesting better adherence), and 
prognosis was assessed using a 6-point scale ranging from 1=best to 6=bad. 
 
The PANSS measures positive and negative symptoms of schizophrenia and general 
psychopathology. It is a 30 item structured interview scored by a trained rater, and 
lasts 30 – 40 minutes. Scores for positive and negative symptomatology, general 
psychopathology, and a total score are calculated.  
 
The CDSS is a nine-item self-rating scale that assesses depression in schizophrenia 
with good reliability [2]. From all items, a total score (mean of ratings) is calculated. A 
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cut off of seven points refers to a specifity of 82% and a sensitivity of 85% for 
detecting major depressive episodes [1]. 
 
Socio demographic variables were assessed at baseline. All other measures were 
assessed at least at visit 1 (baseline) and visit 9 (after 12 months). Observer-rated 
measures were assessed by site-coordinators or co-investigators, e.g. psychiatrists 
(including trainees in psychiatry), research nurses, or psychologists. 
 
Statistical analyses 
To determine if values at baseline differed from values at the 12 months follow up, T-
tests for paired samples and Wilcoxon-tests were used. All tests were calculated with 
PASW Statistics 18.0 for Windows.  
 
Regression analysis 
The dependent variable in regression analysis was the mean of the 12 items of the 
MANSA measuring subjective quality of life 12 months after the study begin. 
Independent variables were the basic socio demographic characteristics (gender, 
age, years of education, occupied at baseline), diagnosis, initial medication group 
(randomisation), psychosocial intervention (yes – no) and antipsychotic medication 
before the beginning of the study (yes – no); baseline quality of life (MANSA sum 
score), number of met and unmet needs, psychopathology (scores of the PANSS 
positive and negative symptoms, and the CDSS total mean score) and the global 
assessment of functioning (GAF) score. Additionally, compliance (Hayward scale) 
and prognosis were included. Only bivariate significant variables were selected for 
the models including several predictors simultaneously. Regression models were 
estimated using PASW Statistics 18.0 for Windows.  
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Structural Equation Models 
Structural equation modelling (SEM) is the method of choice to study (longitudinal) 
interactions when predictor variables are closely interrelated (multicollinearity). To the 
best of our knowledge, there are no studies using SEM to inquire on the longitudinal 
association between needs and quality of life, with the exception of two studies using 
graphical chain modelling [27, 31]. 
We fitted two different structural equation models that both allow for a temporal 
sequence of unmet needs and change variables. The first aimed at replicating the 
results of the regression analysis to provide a base for subsequent models. The 
second model additionally included the number of changes from unmet needs to no 
needs and from unmet needs to met needs. Both models were developed using a 
stepwise deletion of paths. Primarily, a saturated model was fitted, with regression 
paths from all baseline variables to both change variables (met to unmet needs, met 
to no needs), and with regression paths from all variables to quality of life at follow 
up. The model further estimated correlations among baseline variables, and 
correlations among change variables. Starting from the saturated model, the paths 
with the lowest significance were omitted step by step, i.e. the model was run again 
after each deletion. The models were fitted using Mplus [22]. The model fit was 
assessed as suggested by Yu [40]. 
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Results 
From baseline to follow up at 12 months, 78.7% (263 of 334 completers with valid 
PANSS scores at both points in time) reached a 50% reduction on the PANSS total 
score, fulfilling the criterion for treatment success defined by Leucht et al. [20]. Major 
depressive episode (MDE) measured with the CDSS was diagnosed in 36.1% (123 
of 341) at baseline; this was reduced to 3.5% (12 of 340) at 12 months. Most of the 
patients (completers) were in inpatient treatment setting at the beginning of the study 
(89.8%, 307 of 342) but only 4.7% (16 of 340) at follow-up. In sum, clinical 
improvement in the total sample was considerable. 
 
Table 1 shows the descriptive statistics of quality of life and needs, clinical and social 
functioning. At baseline, study completers were more often female, and had more 
(met and unmet) needs, fewer psychosocial interventions, lower quality of life, and 
better compliance as well as prognosis. Fewer completers came from West Europe. 
 
	  	   47	  
Table 1: Quality of life, needs, baseline socio-demographic data, clinical status and 
social functioning.   
 Baseline total  
 
Baseline completers  Drop outs Difference 
drop outs - 
completers7 
 mean ±SD / 
percent 
N mean ±SD / 
percent 
N mean ±SD / 
percent 
N P 
age at baseline 25.98 ±5.55 (498) 26.05 ±5.64 (342) 25.83 ±5.38 (156) 0.618 
gender (women) 40.2% (200) 43.6% (149) 32.7% (51) 0.024 
cultural region -  -  -  0.000 
   West Europe 34.9% (174) 28.9% (99) 48.1% (75) - 
   East/Central Europe 51.4% (256) 59.6% (204) 33.3% (52) - 
   Israel 13.7% (68) 11.4% (39) 18.6% (29) - 
occupation at baseline (yes) 46.6% (231) 46.5% (159) 46.8% (72) 1.000 
antipsychotic naïve at 
baseline 
32.5% (162) 30.7% (105) 36.5% (57) 0.216 
years of education 12.46 (493) 12.58 (341) 12.17 (152) 0.140/0.181 
medication        
…haloperidol 20.7% (103) 19.9% (68) 22.4% (35) 0.227 
…olanzapine 21.1% (105) 24.0% (82) 14.7% (23) - 
…quetiapine 20.9% (104) 20.5% (70) 21.8% (34) - 
…amisulpride 20.9% (104) 20.2% (69) 22.4% (35) - 
…ziprasidone 16.5% (82) 15.5% (53) 18.6% (29) - 
DSM-III-R diagnosis -  -  -  0.603 
   Disorganized, catatonic,  
   undifferentiated 
8.4% (42) 7.3% (25) 10.9% (17) - 
   paranoid 44.8% (223) 45.3% (155) 43.6% (68) - 
   schizophreniform 39.8% (198) 40.1% (137) 39.1% (61) - 
   schizoaffective 7.0% (35) 7.3% (25) 6.4% (10) - 
psychosocial intervention 14.1% (70) 11.4% (39) 19.9% (31) 0.018 
met needs patient, sum 2.59 ±2.57 (470) 2.78 ±2.73 (333) 2.15 ±2.06 (137) 0.007/0.034 
unmet needs patient, sum 2.04 ±2.07 (470) 2.19 ±2.14 (333) 1.66 ±1.82 (137) 0.012/0.013 
MANSA 4.04 ±0.92 (483) 3.98 ±0.90 (339) 4.19 ±0.96 (144) 0.023/0.022 
GAF 40.03 ±13.51 (490) 40.72 ±13.50 (341) 38.46 ±13.44 (149) 0.087/0.107 
PANSS total score 88.53 ±20.63 (487) 89.06 ±20.69 (340) 87.29 ±20.49 (147) 0.386/0.371 
PANSS positive symptoms 23.13 ±6.19 (489) 23.36 ±6.17 (340) 22.59 ±6.23 (149) 0.205/0.138 
PANSS negative symptoms 21.23 ±7.62 (489) 21.14 ±7.73 (341) 21.42 ±7.41 (148) 0.714/0.793 
CDSS, sum score 5.07 ±4.87 (488) 5.27 ±4.88 (341) 4.62 ±4.84 (147) 0.176/0.140 
prognosis by investigators 3.19 ±1.19 (495) 3.10 ±1.18 (342) 3.39 ±1.19 (153) 0.014/0.014 
compliance (at 1 months) 5.57 ±1.20 (453) 5.66 ±1.16 (337) 5.30 ±1.29 (116) 0.006/0.006 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 Significance of differences between baseline completers and dropouts were calculated for 
continuous/count/ordinal variables with t-tests (first p-value), to control for non-normal distributions with the Mann-
Whitney-Test (second p-value) and with the chi-square tests for nominal variables. 
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Figure 1 expresses follow-up values as proportions of baseline values. Comparing 
change in different outcome measures, it becomes clear that changes were most 
pronounced in unmet needs rated by patients, positive symptoms (PANSS), and 
functioning (GAF-score). 
Fig 1: Difference between T1 scores and T9 scores expressed in percent of T1 
values (vertical axis = difference scores). Sample of completers (N=326) 
 
Predictors of Quality of Life using regression analysis 
The baseline variables associated with quality of life at follow up were: Unmet needs, 
functioning (GAF), depression (CDSS), prognosis of patient, gender, age, current 
occupation and years of education. Associations with outcome quality of life changed 
in some time-dependent variables once baseline quality of life was included. Table 2 
shows the multiple regression analysis results for all bivariate significant predictors of 
quality of life at follow up. In multivariate analyses, there model fit improved when 
baseline quality of life was included as a predictor of quality of life assessed at follow-
up (Model 1 vs. Model 2 in Table 2). After including baseline quality of life as a 
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predictor, the baseline assessments of depression, gender and age remained 
significant predictors of quality of life at follow-up (Table 2, Models 2, 3). In contrast, 
the impact of unmet needs on quality of life was no longer significant. Interestingly, 
more depression at baseline was associated with higher quality of life at follow up. 
Younger female patients had higher quality of life at follow up. 
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Table 2: Regression model of MANSA sum score at follow up (dependent variable), 
and the following predictors: baseline clinical variables (Model 1)8, baseline MANSA 
sum score and baseline clinical variables (Model 2)9, baseline MANSA sum score, 
baseline clinical variables and socio-demographic variables (Model 3)10 (N=326).  
 B  Std  B std T P 
Model 1 4.737 .317  14.949 .000 
unmet needs -.057 .023 -.149 -2.488 .013 
CDSS score .016 .010 .094 1.574 .117 
GAF score .006 .004 .097 1.576 .116 
PANSS positive subscale -.003 .008 -.022 -.369 .712 
PANSS negative subscale -.001 .006 -.013 -.216 .829 
Model 2 3.659 .374  9.772 .000 
unmet needs -.034 .023 -.089 -1.507 .133 
CDSS score .026 .010 .158 2.672 .008 
GAF score .004 .004 .073 1.219 .224 
PANSS positive subscale -.003 .008 -.025 -.425 .671 
PANSS negative subscale -.001 .006 -.007 -.117 .907 
MANSA total score .259 .052 .286 4.988 .000 
Model 3 4.399 .493  8.932 .000 
unmet needs -.032 .022 -.082 -1.408 .160 
CDSS total score .026 .010 .158 2.671 .008 
GAF score .003 .004 .055 .933 .351 
PANSS positive subscale -.004 .008 -.027 -.476 .634 
PANSS negative subscale .000 .006 -.001 -.025 .980 
MANSA total score .236 .052 .261 4.572 .000 
patient age at randomisation -.020 .008 -.135 -2.581 .010 
gender -.291 .087 -.176 -3.360 .001 
education (in years) .013 .016 .045 .808 .420 
current occupation .081 .094 .050 .869 .385 
psychosocial intervention  -.229 .133 -.090 -1.723 .086 
prognosis by investigators -.036 .038 -.052 -.938 .349 
  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8 R=.193 R-sq=.037 R-sq-k=.022 
9 R=.327 R-sq=.107 R-sq-k=.090 
10 R=.420 R-sq=.176 R-sq-k=.145 
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Structural Equation Models 
The first simple structural equation model led to nearly the same results as the 
regression model 2 in Table 2 (Figure 2). The longitudinal association between 
baseline unmet needs and follow up quality of life approached p=0.05. The second 
model (Figure 3) additionally included the number of changes of unmet needs to no 
needs or to met needs, and age and gender that were significant in regression model 
3 (Table 2). Change from unmet needs to no needs was more strongly associated 
with quality of life than change from unmet needs to met needs (not significant). 
Fewer unmet needs, more depression, higher baseline quality of life, younger age 
and being female were associated with higher quality of life at follow up. Higher 
depression scores at baseline implicated more change to no needs, and, therefore, 
higher quality of life at follow up. Similarly, a higher level of positive symptoms was 
associated with more change from unmet needs to no needs. Younger female 
patients also had more unmet needs changing to no needs. Only depression and 
unmet needs were associated with the change to met needs (higher depression 
scores was associated with fewer changes to met needs). 
 
 
Fig 2: SEM model replicating regression model 2 (Table 2) (N=330)11 12	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11 Only cross-lagged significant paths are depicted, even though cross sectional and autoregressive paths were 
estimated. Dashed line means nearly significant. 
12 Chi square value=5.671, df=8, P=0.6840; CFI=1.000, TLI=1.037; RMSEA=0.000, SRMR=0.030;Sample of 
completers with values on all variables (N=330). 
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Fig 3: SEM model with same covariates as the model in Figure 2, but including age 
and gender, and differentiating between unmet needs that change to no needs and 
unmet needs that change to met needs (N=330)13 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
13 Chi square value=15.037, df=18, P=0.6595; CFI=1.000, TLI=1.010; RMSEA=0.000, SRMR=0.026; Sample of 
completers with values on all variables (N=330). 
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Discussion 
 
The present study aimed to explore the temporal interrelation between quality of life, 
unmet needs, and potentially associated clinical measures. It used a longitudinal 
sample of patients suffering from first episodes of schizophrenia. We believe there is 
no published study of a comparably homogenous sample at the onset of illness. Not 
surprisingly, there were marked improvements in all social and psychopathological 
outcome indicators over time. While previous studies [30, 31] found a longitudinal 
interrelation between needs and quality of life, this finding was not clearly confirmed 
by our study. We used statistical techniques that allowed for a differentiation between 
needs and the change from unmet needs to no needs. In this sample of first episode 
patients, the change of unmet needs to no needs had a stronger impact on quality of 
life than needs being met. This is self-evident but indicates that the longitudinal 
association between the two constructs depends not on the mere reduction of, but on 
the specification what happened to the unmet needs. 
 
Needs and quality of life 
Our results suggest that the interrelation between quality of life and unmet needs is 
due to cross-sectional rather than longitudinal association in first episode patients. 
The weak evidence for a longitudinal association challenges the assumption of a 
causal interrelation of unmet needs and quality of life. Using conventional regression, 
the association between earlier unmet needs and subsequent quality of life found by 
previous studies was confirmed only if baseline quality of life was omitted. With the 
SEM modelling technique, the longitudinal impact of earlier unmet needs on 
subsequent quality of life was not confirmed unless meeting needs was differentiated 
from needs that changed to no needs during the study. One would expect that any 
	  	   54	  
non-random, strong effect would have shown up unequivocally in both longitudinal 
methodological approaches used. There are not many longitudinal studies with which 
to compare our results. Slade et al. [31] found a relation of earlier unmet needs with 
later quality of life. Another study [30] using random coefficient models found an 
effect of change in unmet needs as well as mean level of unmet need on quality of 
life. Earlier longitudinal studies testing the impact of psychopathology and functioning 
but not needs on quality of life proposed weak or no predictors of subjective quality of 
life using graphical chain modelling [27] or regression analysis [28]. Overall, most 
available studies confirm a longitudinal effect of unmet needs on quality of life. Met 
needs had an even more inconsistent and weaker association with quality of life in 
our study. No study found that more met needs were interrelated with higher quality 
of life. Met needs appear to have the implication of something missing, despite them 
being met. In other words, met needs are better than unmet needs, but cannot be 
equated with health or wellbeing. This is in line with our finding that quality of life was 
more positively influenced by unmet needs that diminished than by unmet needs that 
were met. Therefore, the reduction of unmet needs does not enhance quality of life in 
any case. Meeting a need means that patients are still in need of help in this area of 
life. This result is intuitively compelling. But it sheds another light on what is 
measured when assessing needs, namely, a conglomerate of different aspects of 
illness, treatment and recovery. Granted that treatment implies the meeting of 
patient’s needs, treatment only has a relatively marginal influence on the improving of 
quality of life in our sample. But what has caused the change to no needs that had a 
stronger impact on quality of life? The EUFEST trial describes a homogenous sample 
moving through very different stages of schizophrenia. At baseline, patients were in 
the acute phase, and nearly all in hospital care. At the 12-month follow up, most were 
outpatients and in remission, or stabilization phase of their illness. Additionally, 
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patients suffering from first episode schizophrenia have a more favourable treatment 
response than more chronically ill patients [13]. This might help to explain why there 
were so many needs for care which changed to no needs.  
 
One important question is how unmet needs could be changed to no needs by 
treatment? Is there a direct way from unmet needs to no needs? Is the change to no 
needs also a result of treatment, or has this to be understood as a spontaneous 
remission? Those questions are difficult to answer, but we recommend that results 
based on treatment needs should be interpreted only in combination with other 
measures that validate different aspects of progress. 
 
There are several explanations for the unstable longitudinal interrelation of unmet 
needs and quality of life found in this study. A previous study compared first admitted 
and long term hospitalized patients. It detected stronger associations between needs 
and quality of life in the long term hospitalized sample [26]. As our patients were all in 
early stages of schizophrenia, this could explain the missing associations. In early 
stages of schizophrenia there is considerable change; improving patients may be 
more easily influenced in both positive and negative directions. Other non-treatment 
factors may outweigh treatment factors at the beginning of an illness. Longer 
established schizophrenia is associated with an increasing reliance of patients on 
professionals and health services. The reduced importance of treatment systems in 
our early sample may explain some of the relatively low impact of treatment needs on 
quality of life in our sample. The instability of the regression models may also be due 
to the different situation (e.g. hospital and outpatient care) of patients at baseline and 
at follow up. 
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The vast number of possible influences on the relation between needs and quality of 
life in mind helps explain the inconsistent results in different studies. Further 
influences are whether routine outcome data or research data is used, which 
diagnostic groups are included and in which stage of illness and setting (in hospital 
vs. outpatients) and lastly treatment received. In addition, there are several quality of 
life instruments in use, and needs can be rated by therapists, research assistants or 
the patients themselves.  
 
Other predictors of quality of life 
Longitudinal studies of the interrelation of unmet needs with other outcome measures 
than quality of life are sparse and provided inconsistent results. An advantage of the 
model used is that it explains the change in quality of life. By including baseline 
quality of life, the path from baseline to follow up levels of quality of life represents 
the values remaining stable. The other paths to quality of life explain change. In this 
population of patients, new to their illness, depression was longitudinally more clearly 
interrelated with quality of life than positive and negative symptoms and unmet 
needs. Patients with more depression at baseline had more changes to no needs, 
and therefore, a better quality of life at follow up. The diminishing of unmet needs 
was, in addition to higher depression scores, related to more positive symptoms at 
baseline. Meeting needs was predicted by lower depression scores, but not by 
positive symptoms. There must be patients with marked symptom load at baseline 
who experience alleviation in terms of diminishing need for care for symptoms. This 
in turn influences their subjective quality of life. Interestingly there was no direct effect 
of positive symptoms, but patients with more depression at baseline tended to have a 
better quality of life at follow up. Functioning was not associated with quality of life. 
This is in line with the finding that social functioning and quality of life are 
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independent in schizophrenic patients living in the community [6]. Female gender and 
younger age consistently influenced change and quality of life positively. For further 
research it would be interesting to know more about those complex interrelations. 
 
Future research 
In sum, there is a need for research clearing the following points: The differential impact of 
needs that disappear and need that are met on quality of life should be replicated using more 
measurements and with different patient groups. Treatment research is needed to study the 
processes that lead to change in needs, and to find out what causes needs to disappear. 
Experimental studies are necessary to determine the direction of causality. 
 
Limitations 
Naturalistic studies as ours are limited in their capacity to determine causal effects. If 
the conditions (independent variables) are not manipulated experimentally, causal 
hypotheses cannot be tested with certainty. No definite discrimination between 
correlation and causality is possible. Results of this study should be interpreted as a 
first step in proving that the change from unmet to met needs leads to an 
improvement of quality of life. 
An impediment on the validity of results was drop out. This is a problem of most 
longitudinal studies. Moreover there was a difference between patients who 
completed the study and patients who dropped out for a variety of reasons. Adherent 
patients were those with more needs, higher quality of life, and better compliance as 
well as prognosis at baseline. Strictly speaking, our results are valid only for first 
episode patients with higher baseline quality of life. We refrained from using 
imputation of missing data, because this does not reduce the risk of biased results 
when only two measurements are available. More assessments would allow for 
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better imputation solutions, or for calculating random coefficient models/multilevel 
models that use all available information. 
Finally, the sample of the EUFEST study might not represent the average first 
episode patient, as patients who signed informed consent might differ from patients 
who did not, all patients were in inpatient treatment, and centres were not selected 
randomly. 
 
Conclusions 
This study questions the generally accepted assumption that meeting needs 
enhances quality of life. During the transition from acute to more stable phases of 
illness, unmet needs are associated with outcome quality of life only when they have 
diminished until the outcome assessment. For further research, it is important to 
differentiate meeting unmet needs and unmet needs that change to no needs. 
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